<SEC-DOCUMENT>0001520138-21-000423.txt : 20210811
<SEC-HEADER>0001520138-21-000423.hdr.sgml : 20210811
<ACCEPTANCE-DATETIME>20210811132310
ACCESSION NUMBER:		0001520138-21-000423
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20210808
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210811
DATE AS OF CHANGE:		20210811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOVIE INC.
		CENTRAL INDEX KEY:			0001580149
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				462510769
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39015
		FILM NUMBER:		211162834

	BUSINESS ADDRESS:	
		STREET 1:		2120 COLORADO AVE.
		STREET 2:		SUITE 230
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90404
		BUSINESS PHONE:		310-444-4300

	MAIL ADDRESS:	
		STREET 1:		2120 COLORADO AVE.
		STREET 2:		SUITE 230
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOANTIBIOTICS, INC.
		DATE OF NAME CHANGE:	20130625
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bivi-20210811_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:bivi="http://nanoantibiotics.com/20210808">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_bivi_nanoantibiotics.com_20210808 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20210808_20210808 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001580149 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:EntityCentralIndexKey">0001580149</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-08-08to2021-08-08" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="bivi-20210808.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-08-08to2021-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-08</xbrli:startDate>
        <xbrli:endDate>2021-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>UNITED
STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></span><b><span style="font: 10pt Times New Roman, Times, Serif"><br />
WASHINGTON, D.C. 20549</span></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_90A_edei--DocumentType_c20210808__20210808_zkM8eA0U0NPl"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.75pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CURRENT
REPORT PURSUANT<br />
TO SECTION 13 OR 15(d) OF<br />
THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Date
of Report (Date of earliest event reported) <b><span id="xdx_904_edei--DocumentPeriodEndDate_c20210808__20210808_zjHH8J0VVOcd"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 8, 2021</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90C_edei--EntityRegistrantName_c20210808__20210808_zuWoMlDc0Eg3"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:EntityRegistrantName">BioVie Inc.</ix:nonNumeric></span></span></b></span><b><span style="text-decoration: underline"><span style="font: 10pt Times New Roman, Times, Serif"><br />
</span></span></b><span style="font: 10pt Times New Roman, Times, Serif">(Exact Name of Registrant as Specified in Its Charter)</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20210808__20210808_zCH7H0Pq6oda"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityFileNumber_c20210808__20210808_zWJk90qfd1U2"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:EntityFileNumber">000-55292</ix:nonNumeric></span></b></span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20210808__20210808_zbgqwIYPLvpl"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:EntityTaxIdentificationNumber">46-2510769</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State
    or Other Jurisdiction<br />
    of Incorporation)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission
    File Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S.
    Employer Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20210808__20210808_zhPY2IlW4c49"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:EntityAddressAddressLine1">2120 Colorado Avenue</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20210808__20210808_zQNJgOq6Z2Q5"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:EntityAddressAddressLine2">#230</ix:nonNumeric></span><br />
    <span id="xdx_909_edei--EntityAddressCityOrTown_c20210808__20210808_zt3mQJZo6ez9"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:EntityAddressCityOrTown">Santa Monica</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20210808__20210808_z8MvLrzKnH61"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityAddressPostalZipCode_c20210808__20210808_zALbFurAmzi"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:EntityAddressPostalZipCode">90404</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
    of Principal Executive Offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip
    Code)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_904_edei--CityAreaCode_c20210808__20210808_z6GzHV42bIig"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:CityAreaCode">(310)</ix:nonNumeric></span> <span id="xdx_900_edei--LocalPhoneNumber_c20210808__20210808_z6J0gxzz07gf"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:LocalPhoneNumber">444-4300</ix:nonNumeric></span><br />
</span></b>(Registrant&#146;s Telephone Number, Including Area Code)</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center">&#160;</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Former
Name or Former Address, if Changed Since Last Report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol(s)</span></td>
    <td style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of each exchange on which<br />
    registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--Security12bTitle_c20210808__20210808_zxHokUpj4ZWg"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:Security12bTitle">Class A Common Stock</ix:nonNumeric></span>, par value $0.0001 per share</span></td>
    <td style="border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--TradingSymbol_c20210808__20210808_zYrLwzApQX1"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" name="dei:TradingSymbol">BIVI</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The <span id="xdx_905_edei--SecurityExchangeName_c20210808__20210808_zcwCF3gxKRo6"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market, LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span id="xdx_901_edei--WrittenCommunications_c20210808__20210808_zK09YRfLMwr5"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--SolicitingMaterial_c20210808__20210808_z6hkb0VE09Z7"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20210808__20210808_zPZK3XM3DMh7"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.3in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20210808__20210808_zHDkyIwHmaT2"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20210808__20210808_zgjcKr3tzEJ1"><ix:nonNumeric contextRef="From2021-08-08to2021-08-08" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 0pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item&#160;1.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Entry
    into Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">On
August 8, 2021, BioVie Inc. (the &#147;Company&#148;) entered into an underwriting agreement (the &#147;Underwriting Agreement&#148;)
with ThinkEquity, a division of Fordham Financial Management, Inc., as representative of the several underwriters identified therein
(the &#147;Underwriters&#148;), relating to public offering (the &#147;Offering&#148;) of 2,500,000 shares of the Company&#146;s
Class A common stock, par value $0.0001 per share (the &#147;Firm Shares&#148;) by the Company. Pursuant to the Underwriting Agreement,
the Company has also granted the Underwriters a 45-day option to purchase up to an additional 375,000 shares (the &#147;Option Shares&#148;
and together with the Firm Shares, the &#147;Shares&#148;) of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">The
Underwriters agreed to purchase the Shares pursuant to the Underwriting Agreement, at a price of $7.68 per share. The shares of the Company&#146;s
common stock were offered, issued and sold under a prospectus supplement and accompanying prospectus filed with the Securities and Exchange
Commission (the &#147;SEC&#148;)&#160;pursuant to an&#160;effective shelf registration statement filed with the SEC on Form S-3 (Registration
No.&#160;333- 252386) pursuant to the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). EF Hutton, division of Benchmark
Investments, LLC, acted as a financial advisor for the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">The
Underwriting Agreement contained customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations
of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were
made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and were
subject to limitations agreed upon by the contracting parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">The
Underwriting Agreement is filed as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the terms
of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Sherman &amp; Howard
L.L.C. relating to the legality of the issuance and sale of the Shares in the Offering is attached as Exhibit 5.1 hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 10%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                          7.01</b></span></td><td style="text-align: justify; width: 90%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Regulation
FD Disclosure.</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">On August 8, 2021, the Company issued a press release announcing that it had priced the Offering. On August 11, 2021, the Company issued
a press release announcing that it had closed the Offering with respect to the Firm Shares. A copy of these press releases are attached
as Exhibits 99.1 and 99.2 to this Current Report and incorporated by reference into this Item 7.01.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 10%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
8.01</b></span></td><td style="text-align: justify; width: 90%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Other
Events.</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">On
August 11, 2021, the Company closed the Offering of the Shares at a price to the public of $8.00 per share for net proceeds of approximately
$17.8 million, after deducting the underwriting discount and estimated offering expenses payable by the Company. The Shares are listed
on The NASDAQ Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 10%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
                          9.01</b></span></td><td style="text-align: justify; width: 90%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Financial
Statements and Exhibits</span></b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(a)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 87%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210811_8kex1z1.htm"><span style="font: 10pt Times New Roman, Times, Serif">1.1</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210811_8kex1z1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Underwriting
    Agreement between the Company and ThinkEquity, a division of Fordham Financial Management, Inc., as representatives of the several
    Underwriters, dated August 8, 2021.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210811_8kex5z1.htm"><span style="font: 10pt Times New Roman, Times, Serif">5.1</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210811_8kex5z1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Opinion
    of Sherman &amp; Howard L.L.C.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210811_8kex5z1.htm"><span style="font: 10pt Times New Roman, Times, Serif">23.1</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210811_8kex5z1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Consent
    of Sherman &amp; Howard L.L.C. (included in Exhibit 5.1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210811_8kex99z1.htm"><span style="font: 10pt Times New Roman, Times, Serif">99.1</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210811_8kex99z1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Press
    Release, dated August 8, 2021</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210811_8kex99z2.htm"><span style="font: 10pt Times New Roman, Times, Serif">99.2</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="bivi-20210811_8kex99z2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Press
    Release, dated August 11, 2021</span></a></td></tr>
  </table>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Dated:
August 11, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>BIOVIE
    INC.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 38%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">/s/
    Joanne Wendy Kim</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Name:&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Joanne
    Wendy Kim</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</p></div>
    <!-- Field: /Page -->



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6PHSdCLo3HSriFBkivhaXSXFrRlqn+yT/0rohhkBI7j25QoRiQ2tdIcNlmWdwwrqplEPIsURGc0XvSLe7BPzM8aatY2Vcv/7AlDyDnpmO5srfe2erLRYJRLOxlONYQhQn0wks9iL46imZUhdonFYVKFPAkalhjU5xN3w4qRcZqrs+6YxsNZkE5Cga5DfEkYzhQK16Et8tZFkqgrCvQGyYHs035mEd1bCqsPZZdkD/HXwA13ZJDQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>bivi-20210811_8kex1z1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THINKEQUITY,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>as Representative of the Several Underwriters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

</div></center>
<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>UNDERWRITING AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">New York, New York<BR>
August 8, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ThinkEquity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A Division of Fordham Financial Management, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As Representative of the several Underwriters named on Schedule 1 attached
hereto<BR>
17 State Street, 22<FONT STYLE="font-size: 12.5pt"><SUP>nd</SUP></FONT> Fl</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, NY 10004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned, BioVie Inc.,
a corporation formed under the laws of the State of Nevada (collectively with its subsidiaries and affiliates, including, without limitation,
all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of BioVie
Inc. (the &#8220;Company&#8221;), hereby confirms its agreement (this &#8220;Agreement&#8221;) with ThinkEquity, a division of Fordham
Financial Management, Inc. (hereinafter referred to as &#8220;you&#8221; (including its correlatives) or the &#8220;Representative&#8221;),
and with the other underwriters named on <U>Schedule 1</U> hereto for which the Representative is acting as representative (the &#8220;Representative&#8221;
and such other underwriters being collectively called the &#8220;Underwriters&#8221; or, individually, an &#8220;Underwriter&#8221;) as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif">1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><U>Purchase and Sale of Shares</U>.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1 <I><U>Firm Shares</U>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.1.1. <U>Nature and Purchase of
Firm Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i) On the basis of the representations
and warranties herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell to the
several Underwriters, an aggregate of 2,500,000 shares (the &#8220;Firm Shares&#8221; or &#8220;Public Securities&#8221;) of the Company&#8217;s
Class A common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">(ii) The Underwriters, severally and not jointly, agree
to purchase from the Company the number of Firm Shares set forth opposite their respective names on <U>Schedule 1</U> attached hereto
and made a part hereof at a purchase price of $7.68 per Firm Share (96% of the per Firm Share offering price). The Firm Shares are to
be offered initially to the public at the offering price set forth on the cover page of the Prospectus (as defined in Section 2.1.1 hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">1.1.2. <U>Shares Payment and Delivery</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i) Delivery and payment for the
Firm Shares shall be made at 10:00 a.m., Eastern time, on the second (2<FONT STYLE="font-size: 12.5pt"><SUP>nd</SUP></FONT>) Business
Day following the date hereof (or the third (3<FONT STYLE="font-size: 12.5pt"><SUP>rd</SUP></FONT>) Business Day following the date hereof
(if the Firm Shares are priced, as contemplated by Rule 15c-6-1(c) under the Exchange Act, after 4:30 p.m., Eastern time) or at such earlier
time as shall be agreed upon by the Representative and the Company, at the offices of Sheppard, Mullin, Richter &amp; Hampton LLP, 30
Rockefeller Plaza, 39<SUP>th</SUP> Floor, New York, NY 10112 (&#8220;Representative Counsel&#8221;), or at such other place (or remotely
by facsimile or other electronic transmission) as shall be agreed upon by the Representative and the Company. The hour and date of delivery
and payment for the Firm Shares is called the &#8220;Closing Date.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii) Payment for the Firm Shares
shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company upon delivery of the
certificates (in form and substance satisfactory to the Underwriters) representing the Firm Shares (or through the facilities of the Depository
Trust Company (&#8220;DTC&#8221;)) for the account of the Representative. The Firm Shares shall be registered in such name or</P>

</div></center>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">names and in such authorized denominations as the
Representative may request in writing at least two (2) full Business Days prior to the Closing Date. The Company shall not be obligated
to sell or deliver the Firm Shares except upon tender of payment by the Representative for all of the Firm Shares. The term &#8220;Business
Day&#8221; means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated
by law to close in New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.2 <I>Over-allotment Option</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">1.2.1. <FONT STYLE="font-size: 11pt"><U>Option
Shares</U>. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Shares, the Company
hereby grants to the Underwriters an option to purchase up to 375,000 additional shares of Common Stock, representing fifteen percent
(15%) of the Firm Shares sold in the offering, from the Company (the &#8220;Over-allotment Option&#8221;). Such 375,000 additional shares
of Common Stock, the net proceeds of which will be deposited with the Company&#8217;s account, are hereinafter referred to as &#8220;Option
Shares.&#8221; The purchase price to be paid per Option Share shall be equal to the price per Firm Share set forth in Section 1.1.1 hereof.
The Firm Shares and the Option Shares are hereinafter referred to together as the &#8220;Public Securities.&#8221; The offering and sale
of the Public Securities is hereinafter referred to as the &#8220;Offering.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">1.2.2. <FONT STYLE="font-size: 11pt"><U>Exercise
of Option</U>. The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Representative as to all (at
any time) or any part (from time to time) of the Option Shares within 45 days after the Effective Date. The Underwriters shall not be
under any obligation to purchase any Option Shares prior to the exercise of the Over-allotment Option. The Over-allotment Option granted
hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed in writing by overnight
mail or facsimile or other electronic transmission setting forth the number of Option Shares to be purchased and the date and time for
delivery of and payment for the Option Shares (the &#8220;Option Closing Date&#8221;), which shall not be later than one (1) full Business
Days after the date of the notice or such other time as shall be agreed upon by the Company and the Representative, at the offices of
Representative Counsel or at such other place (including remotely by facsimile or other electronic transmission) as shall be agreed upon
by the Company and the Representative. If such delivery and payment for the Option Shares does not occur on the Closing Date, the Option
Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option with respect to all or any portion of the
Option Shares, subject to the terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters
the number of Option Shares specified in such notice and (ii) each of the Underwriters, acting severally and not jointly, shall purchase
that portion of the total number of Option Shares then being purchased as set forth in <U>Schedule 1</U> opposite the name of such Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 76.5pt">1.2.3. <FONT STYLE="font-size: 11pt"><U>Payment
and Delivery</U>. Payment for the Option Shares shall be made on the Option Closing Date by wire transfer in Federal (same day) funds,
payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the Underwriters) representing
the Option Shares (or through the facilities of DTC) for the account of the Underwriters. The Option Shares shall be registered in such
name or names and in such authorized denominations as the Representative may request in writing at least one (1) full Business Day prior
to the Option Closing Date. The Company shall not be obligated to sell or deliver the Option Shares except upon tender of payment by the
Representative for applicable Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. <U>Representations and Warranties of the Company</U>.
The Company represents and warrants to the Underwriters as of the Applicable Time (as defined below), as of the Closing Date, and as of
the Option Closing Date, if any, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1 <I><U>Filing of Registration
Statement</U>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</div></center>
<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.1.1. <U>Pursuant to the Securities
Act</U>. The Company has filed with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;) a &#8220;shelf&#8221; registration
statement, and an amendment or amendments thereto, on Form S-3 (File No. 333-252386), including any related prospectus or prospectuses
for the registration of the Public Securities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), which became
effective as of February 2, 2021 (the &#8220;Effective Date&#8221;), including a base prospectus relating to the Public Securities (the
&#8220;Base Prospectus&#8221;), and such amendments and supplements thereto as may have been required to the date of this Agreement, which
registration statement, Base Prospectus and amendment or amendments have been prepared by the Company in all material respects in conformity
with the requirements of the Securities Act and the rules and regulations of the Commission under the Securities Act (the &#8220;Securities
Act Regulations&#8221;) and contains and will contain all material statements that are required to be stated therein in accordance with
the Securities Act and the Securities Act Regulations. Except as the context may otherwise require, such registration statement, as amended,
on file with the Commission at the time the registration statement became effective (including the Base Prospectus included in the registration
statement, financial statements, schedules, exhibits and all other documents filed as a part thereof or incorporated therein and all information
deemed to be a part thereof as of the Effective Date pursuant to Rule 430B of the Securities Act Regulations (the &#8220;Rule 430B Information&#8221;)),
is referred to herein as the &#8220;Registration Statement.&#8221; If the Company files any registration statement pursuant to Rule 462(b)
of the Securities Act Regulations, then after such filing, the term &#8220;Registration Statement&#8221; shall include such registration
statement filed pursuant to Rule 462(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.1.2. Each preliminary prospectus
supplement, if any, to the Base Prospectus (including the Base Prospectus as so supplemented) that described the Public Securities and
the Offering thereof, that omitted the Rule 430B Information and that was used prior to the filing of the final prospectus supplement
referred to in the following sentence, is herein called a &#8220;Preliminary Prospectus.&#8221; Promptly after the execution and delivery
of this Agreement, the Company will prepare and file with the Commission a final prospectus supplement to the Base Prospectus relating
to the Public Securities and the Offering thereof in accordance with the provisions of Rule 430B and Rule 424(b) of the Securities Act
Regulations. Such final prospectus supplement (including the Base Prospectus as so supplemented), in the form filed with the Commission
pursuant to Rule 424(b) under the Securities Act is herein called the &#8220;Prospectus.&#8221; Any reference herein to the Base Prospectus,
any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant
to Item 12 of Form S-3 under the Securities Act as of the date of such prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;Applicable Time&#8221;
means 6:15 p.m., Eastern time, on the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;Disclosure Package&#8221;
means the Preliminary Prospectus, any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, and the information
included on <U>Schedule 2-A</U> hereto, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;Issuer Free Writing Prospectus&#8221;
means any &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433 of the Securities Act Regulations (&#8220;Rule 433&#8221;),
including without limitation any &#8220;free writing prospectus&#8221; (as defined in Rule 405 of the Securities Act Regulations) relating
to the Public Securities that is (i) required to be filed with the Commission by the Company, (ii) a &#8220;road show that is a written
communication&#8221; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt
from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Public Securities or of the Offering
that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required
to be filed, in the form retained in the Company&#8217;s records pursuant to Rule 433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;Issuer General Use Free
Writing Prospectus&#8221; means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors
(other than a &#8220;<I>bona fide</I> electronic road show,&#8221; as defined in Rule 433 (the &#8220;Bona Fide Electronic Road Show&#8221;)),
as evidenced by its being specified in <U>Schedule 2-B</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;Issuer Limited Use Free
Writing Prospectus&#8221; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.1.3. <U>Pursuant to the Exchange
Act</U>. The Company has filed with the Commission a Form 8-A (File Number 001-39015) providing for the registration pursuant to Section
12(b) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), of the shares of Common Stock. The registration
of the shares of</P>

</div></center>
<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common Stock under the Exchange Act has been declared
effective by the Commission on or prior to the date hereof. The Company has taken no action designed to, or likely to have the effect
of, terminating the registration of the shares of Common Stock under the Exchange Act, nor has the Company received any notification that
the Commission is contemplating terminating such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.2 <U>Stock Exchange Listing</U>. The shares of Common
Stock have been approved for listing on The Nasdaq Capital Market (the &#8220;Exchange&#8221;), and the Company has taken no action designed
to, or likely to have the effect of, delisting the shares of Common Stock from the Exchange, nor has the Company received any notification
that the Exchange is contemplating terminating such listing except as described in the Registration Statement, the Disclosure Package
and the Prospectus. The Company has submitted the Listing of Additional Shares Notification Form with the Exchange with respect to the
Offering of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3 <U>No Stop Orders, etc</U>.
Neither the Commission nor, to the Company&#8217;s knowledge, any state regulatory authority has issued any order preventing or suspending
the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted or, to the Company&#8217;s knowledge,
threatened to institute, any proceedings with respect to such an order. The Company has complied with each request (if any) from the Commission
for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.4 <U>Disclosures in Registration
Statement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.4.1. <U>Compliance with Securities
Act and 10b-5 Representation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(i) Each of the Registration Statement
and any post-effective amendment thereto, at the time it became effective, complied in all material respects with the requirements of
the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including the prospectus filed as part of the Registration
Statement as originally filed or as part of any amendment or supplement thereto, and the Prospectus, at the time each was filed with the
Commission, complied in all material respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary
Prospectus delivered to the Underwriters for use in connection with this Offering and the Prospectus was or will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(ii) Neither the Registration
Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date, or at the Option Closing Date
(if any) contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iii) The Disclosure Package,
as of the Applicable Time, at the Closing Date, or at the Option Closing Date (if any) did not, does not and will not include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; and each Issuer Limited Use Free Writing Prospectus hereto does not conflict with the information
contained in the Registration Statement, any Preliminary Prospectus or the Prospectus, and each such Issuer Limited Use Free Writing Prospectus,
as supplemented by and taken together with the Prospectus as of the Applicable Time, did not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading; provided, however, that this representation and warranty shall not apply to statements made or statements omitted
in reliance upon and in conformity with written information furnished to the Company with respect to the Underwriters by the Representative
expressly for use in the Registration Statement or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge
and agree that such information provided by or on behalf of any Underwriter consists solely of the following disclosure contained in the
&#8220;Underwriting&#8221; section of the Prospectus: the first sentence in the first paragraph and the table in the second paragraph
under the caption &#8220;Underwriting&#8221; and the first three paragraphs under the caption &#8220;Underwriting &#8211; Price Stabilization,
Short-Positions and Penalty Bids&#8221; (the &#8220;Underwriters&#8217; Information&#8221;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in">(iv) Neither the Prospectus nor
any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission
pursuant to Rule 424(b), at the Closing Date or at any Option Closing Date, included, includes or will include an untrue statement of
a material</P>

</div></center>
<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">fact or omitted, omits or will omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
provided, however, that this representation and warranty shall not apply to the Underwriters&#8217; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1.5in">(v) The documents incorporated
by reference in the Registration Statement, the Disclosure Package and the Prospectus, when they became effective or were filed with the
Commission, as the case may be, conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable,
and the rules and regulations of the Commission thereunder and none of such documents contained any untrue statement of a material fact
or omitted to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement,
the Disclosure Package and the Prospectus, when such documents become effective or are filed with the Commission, as the case may be,
will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and the rules and
regulations of the Commission thereunder, and will not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.4.2. <U>Disclosure of Agreements</U>.
The agreements and documents described in the Registration Statement, the Disclosure Package and the Prospectus conform in all material
respects to the descriptions thereof contained or incorporated by reference therein and there are no agreements or other documents required
by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the Disclosure Package and the
Prospectus or to be filed with the Commission as exhibits to the Registration Statement or to be incorporated by reference in the Registration
Statement, the Disclosure Package or the Prospectus, that have not been so described or filed or incorporated by reference. Each agreement
or other instrument (however characterized or described) to which the Company is a party or by which it is or may be bound or affected
and (i) that is referred to or incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus, or
(ii) is material to the Company&#8217;s business, has been duly authorized and validly executed by the Company, is in full force and effect
in all material respects and is enforceable against the Company and, to the Company&#8217;s knowledge, the other parties thereto, in accordance
with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#8217;
rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities
laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable
defenses and to the discretion of the court before which any proceeding therefor may be brought. None of such agreements or instruments
has been assigned by the Company, and none of the Company nor, to the best of the Company&#8217;s knowledge, any other party is in default
thereunder and, to the best of the Company&#8217;s knowledge, no event has occurred that, with the lapse of time or the giving of notice,
or both, would constitute a default thereunder. To the best of the Company&#8217;s knowledge, performance by the Company of the material
provisions of such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, ordinance,
judgment, order or decree of any governmental or regulatory agency, body, authority or court, domestic or foreign, having jurisdiction
over the Company or any of its assets or businesses (each, a &#8220;Governmental Entity&#8221;), including, without limitation, those
relating to environmental laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.4.3. <U>Prior Securities Transactions</U>.
No securities of the Company have been sold by the Company or by or on behalf of, or for the benefit of, any person or persons controlling,
controlled by or under common control with the Company, except as disclosed in the Registration Statement, the Disclosure Package and
the Preliminary Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.4.4. <U>Regulations</U>.
The disclosures in the Registration Statement, the Disclosure Package and the Prospectus concerning the effects of federal, state, local
and all foreign regulation on the Offering and the Company&#8217;s business as currently contemplated are accurate, correct and complete
in all material respects and no other such regulations are required to be disclosed in the Registration Statement, the Disclosure Package
and the Prospectus which are not so disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.4.5. <U>No Other Distribution
of Offering Materials</U>. The Company has not, directly or indirectly, distributed and will not distribute any offering material in connection
with the Offering other than any Preliminary</P>

</div></center>
<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prospectus, the Disclosure Package, the Prospectus
and other materials, if any, permitted under the Securities Act and consistent with Section 3.2 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.5 <U>Changes After Dates in
Registration Statement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.5.1. <U>No Material Adverse Change</U>.
Since the respective dates as of which information is given in the Registration Statement, the Disclosure Package and the Prospectus,
except as otherwise specifically stated therein: (i) there has been no material adverse change or development in the business of the Company
which would involve a material adverse change or prospective material adverse change, whether or not arising from transactions in the
ordinary course of business, in or affecting the business, management, condition (financial or otherwise), results of operations, stockholders&#8217;
equity, assets, properties or prospects of the Company taken as a whole (a &#8220;Material Adverse Change&#8221;); (ii) there have been
no material transactions entered into by the Company, other than as contemplated pursuant to this Agreement; (iii) no officer or director
of the Company has resigned from any position with the Company; and (iv) the Company has not sustained any material loss or interference
with its business or properties from fire, explosion, flood, earthquake, hurricane, accident or other calamity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.5.2. <U>Recent Securities Transactions,
etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement, the Disclosure Package and
the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration Statement, the Disclosure
Package and the Prospectus, the Company has not: (i) issued any securities or incurred any liability or obligation, direct or contingent,
for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect to its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.6 <U>Disclosures in Commission
Filings</U>. Since January 1, 2017, (i) none of the Company&#8217;s filings with the Commission contained any untrue statement of a material
fact or omitted to state any material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; and (ii) the Company has made all filings with the Commission required under the Exchange Act and
the rules and regulations of the Commission promulgated thereunder (the &#8220;Exchange Act Regulations&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.7 <U>Independent Accountants</U>.
To the knowledge of the Company, EisnerAmper, LLP (the &#8220;Auditor&#8221;), whose report is filed with the Commission and incorporated
by reference in the Registration Statement, the Disclosure Package and the Prospectus, is an independent registered public accounting
firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting Oversight Board. The Auditor
has not, during the periods covered by the financial statements included or incorporated by reference in the Registration Statement, the
Disclosure Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.8 <U>Financial Statements, etc</U>.
The financial statements, including the notes thereto and supporting schedules included or incorporated by reference in the Registration
Statement, the Disclosure Package and the Prospectus, fairly present the financial position and the results of operations of the Company
at the dates and for the periods to which they apply; and such financial statements have been prepared in conformity with U.S. generally
accepted accounting principles (&#8220;GAAP&#8221;), consistently applied throughout the periods involved (provided that unaudited interim
financial statements are subject to year-end audit adjustments that are not expected to be material in the aggregate and do not contain
all footnotes required by GAAP); and the supporting schedules included or incorporated by reference in the Registration Statement present
fairly the information required to be stated therein. Except as included or incorporated by reference therein, no historical or pro forma
financial statements are required to be included or incorporated by reference in the Registration Statement, the Disclosure Package or
the Prospectus under the Securities Act or the Securities Act Regulations. The as adjusted financial information and the related notes,
if any, included or incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus have been properly
compiled and prepared in accordance with the applicable requirements of the Securities Act, the Securities Act Regulations, the Exchange
Act or the Exchange Act Regulations and present fairly the information shown therein, and the assumptions used in the preparation thereof
are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein.
All disclosures contained in the Registration Statement, the Disclosure Package or the Prospectus, or incorporated or deemed incorporated
by reference therein, regarding &#8220;non-GAAP financial measures&#8221; (as such term is defined by the rules and regulations of the
Commission), if any, comply with Regulation G of the Exchange Act and Item 10 of</P>
</div></center>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regulation S-K of the Securities Act, to the extent
applicable. Each of the Registration Statement, the Disclosure Package and the Prospectus discloses all material off-balance sheet transactions,
arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated entities or other
persons that may have a material current or future effect on the Company&#8217;s financial condition, changes in financial condition,
results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as
disclosed in the Registration Statement, the Disclosure Package and the Prospectus, (a) neither the Company nor any of its direct and
indirect subsidiaries, including each entity disclosed or described in the Registration Statement, the Disclosure Package and the Prospectus
as being a subsidiary of the Company, has incurred any material liabilities or obligations, direct or contingent, or entered into any
material transactions other than in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any
distribution of any kind with respect to its capital stock, (c) there has not been any change in the capital stock of the Company, or,
other than in the course of business, any grants under any stock compensation plan, and (d) there has not been any material adverse change
in the Company&#8217;s long-term or short-term debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.9 <U>Authorized Capital; Options,
etc</U>. The Company had, at the date or dates indicated in the Registration Statement, the Disclosure Package and the Prospectus, the
duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions stated in the Registration Statement,
the Disclosure Package and the Prospectus, the Company will have on the Closing Date the adjusted stock capitalization set forth therein.
Except as set forth in, or contemplated by, the Registration Statement, the Disclosure Package and the Prospectus, on the date hereof,
as of the Applicable Time and on the Closing Date, there will be no stock options, warrants, or other rights to purchase or otherwise
acquire any authorized, but unissued shares of Common Stock of the Company or any security convertible or exercisable into shares of Common
Stock of the Company, or any contracts or commitments to issue or sell shares of Common Stock or any such options, warrants, rights or
convertible securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.10 <U>Valid Issuance of Securities,
etc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.10.1. <U>Outstanding Securities</U>.
All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement have been duly authorized
and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission or similar rights with respect
thereto or put rights, and are not subject to personal liability by reason of being such holders; and none of such securities were issued
in violation of the preemptive rights, rights of first refusal or rights of participation of any holders of any security of the Company
or similar contractual rights granted by the Company. The authorized shares of Common Stock conform in all material respects to all statements
relating thereto contained in the Registration Statement, the Disclosure Package and the Prospectus. The offers and sales of the outstanding
shares of Common Stock were at all relevant times either registered under the Securities Act and the applicable state securities or &#8220;blue
sky&#8221; laws or, based in part on the representations and warranties of the purchasers of such Shares, exempt from such registration
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.10.2. <U>Securities Sold Pursuant
to this Agreement</U>. The Public Securities have been duly authorized for issuance and sale and, when issued and paid for pursuant to
the terms of this Agreement, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject
to personal liability by reason of being such holders; the Public Securities are not and will not be subject to the preemptive rights
of any holders of any security of the Company or similar contractual rights granted by the Company; and all corporate action required
to be taken for the authorization, issuance and sale of the Public Securities has been duly and validly taken. The Public Securities conform
in all material respects to all statements with respect thereto contained in the Registration Statement, the Disclosure Package and the
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.11 <U>Registration Rights of
Third Parties</U>. Except as set forth in the Registration Statement, the Disclosure Package and the Prospectus, no holders of any securities
of the Company or any rights exercisable for or convertible or exchangeable into securities of the Company have the right to require the
Company to register any such securities of the Company under the Securities Act or to include any such securities in a registration statement
to be filed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.12 <U>Validity and Binding Effect
of Agreements</U>. This Agreement has been duly and validly authorized by the Company, and, when executed and delivered, will constitute,
the valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except: (i) as such enforceability
may be limited by</P>

</div></center>
<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">bankruptcy, insolvency, reorganization or similar
laws affecting creditors&#8217; rights generally; (ii) as enforceability of any indemnification or contribution provision may be limited
under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable
relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.13 <U>No Conflicts, etc</U>.
The execution, delivery and performance by the Company of this Agreement and all ancillary documents, the consummation by the Company
of the transactions herein and therein contemplated and the compliance by the Company with the terms hereof and thereof do not and will
not, with or without the giving of notice or the lapse of time or both: (i) result in a material breach of, or conflict with any of the
terms and provisions of, or constitute a material default under, or result in the creation, modification, termination or imposition of
any lien, charge, mortgage, pledge, security interest, claim, equity, trust or other encumbrance, preferential arrangement or restriction
of any kind whatsoever or encumbrance upon any portion of any property or assets of the Company pursuant to the terms of any indenture,
mortgage, deed of trust, note, lease, loan agreement or any other agreement or instrument, license or permit to which the Company is a
party or as to which any property of the Company is a party, except as set forth in the Registration Statement, Disclosure Package and
Prospectus; (ii) result in any violation of the provisions of the Company&#8217;s Articles of Incorporation (as the same may be amended
or restated from time to time, the &#8220;Charter&#8221;) or the by-laws of the Company (as the same may be amended or restated from time
to time, the &#8220;By-laws&#8221;); or (iii) violate any existing applicable law, rule, regulation, judgment, order or decree of any
Governmental Entity as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.14 <U>No Defaults; Violations</U>.
No material default exists in the due performance and observance of any term, covenant or condition of any material license, contract,
indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing an obligation for
borrowed money, or any other material agreement or instrument to which the Company is a party or by which the Company may be bound or
to which any of the properties or assets of the Company is subject. The Company is not in violation of any term or provision of its Charter
or By-laws, or in violation of any franchise, license, permit, applicable law, rule, regulation, judgment, order or decree of any Governmental
Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.15 <U>Corporate Power; Licenses;
Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.15.1. <U>Conduct of Business</U>.
Except as described in the Registration Statement, the Disclosure Package and the Prospectus, the Company has all requisite corporate
power and authority, and has all necessary consents, authorizations, approvals, registrations, orders, licenses, certificates and permits
of and from all governmental regulatory officials and bodies that it needs as of the date hereof to conduct its business purpose as described
in the Registration Statement, the Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.15.2. <U>Transactions Contemplated
Herein</U>. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions and conditions
hereof, and all consents, authorizations, approvals, registrations, and orders required in connection therewith have been obtained. No
consent, authorization or order of, and no filing with, any court, government agency or other body is required for the valid issuance,
sale and delivery of the Public Securities and the consummation of the transactions and agreements contemplated by this Agreement and
as contemplated by the Registration Statement, the Disclosure Package and the Prospectus, except with respect to applicable federal and
state securities laws and the rules and regulations of the Exchange and the Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.16 <U>D&amp;O Questionnaires</U>.
To the Company&#8217;s knowledge, all information contained in the questionnaires (the &#8220;Questionnaires&#8221;) completed by each
of the Company&#8217;s directors and officers and made available to the Representative (the &#8220;Insiders&#8221;) as supplemented by
all information concerning the Company&#8217;s directors, officers and principal stockholders as described in the Registration Statement,
the Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined in Section 2.26 below), provided to the Underwriters,
is true and correct in all material respects and the Company has not become aware of any information which would cause the information
disclosed in the Questionnaires to become materially inaccurate and incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.17 <U>Litigation; Governmental
Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending
or, to the Company&#8217;s knowledge, threatened against, or involving the Company, or, to the Company&#8217;s knowledge, any executive
officer or director which has not been</P>
</div></center>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">disclosed in the Registration Statement, the Disclosure
Package and the Prospectus or in connection with the Company&#8217;s listing application for the listing of the Public Securities on the
Exchange, and which if resolved adversely to the Company would result in a Material Adverse Change or otherwise affect the Company&#8217;s
ability to consummate the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.18 <U>Good Standing</U>. The
Company has been duly incorporated and is validly existing as a corporation and is in good standing under the laws of the State of Nevada
as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction in which its ownership
or lease of property or the conduct of business requires such qualification, except where the failure to qualify, singularly or in the
aggregate, would not have or reasonably be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.19 <U>Insurance</U>. The Company
carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering such risks which the Company
believes are adequate, including, but not limited to, directors and officers insurance coverage at least equal to $5,000,000 and all such
insurance is in full force and effect. The Company has no reason to believe that it will not be able (i) to renew its existing insurance
coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate
to conduct its business as now conducted and at a cost that would not result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.20 <U>Transactions Affecting
Disclosure to FINRA</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.20.1. <U>Finder&#8217;s Fees</U>.
Except as described in the Registration Statement, the Disclosure Package and the Prospectus, there are no claims, payments, arrangements,
agreements or understandings relating to the payment of a finder&#8217;s, consulting or origination fee by the Company or any Insider
with respect to the sale of the Public Securities hereunder or any other arrangements, agreements or understandings of the Company or,
to the Company&#8217;s knowledge, any of its stockholders that may affect the Underwriters&#8217; compensation, as determined by FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.20.2. <U>Payments Within Twelve
(12) Months</U>. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, the Company has not made
any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&#8217;s fee, consulting fee or otherwise,
in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided capital to
the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation or association with any
FINRA member, within the twelve (12) months prior to the date hereof, other than the payment to the Underwriters as provided hereunder
in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.20.3. <U>Use of Proceeds</U>.
None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates, except as specifically
authorized herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.20.4. <U>FINRA Affiliation</U>.
There is no (i) officer or director of the Company, or (ii) beneficial owner of 10% or more of any class of the Company&#8217;s equity
and equity-linked securities that is an affiliate or associated person of a FINRA member participating in the Offering (as determined
in accordance with the rules and regulations of FINRA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.20.5. <U>Information</U>. All
information provided by the Company and to the Company&#8217;s knowledge, its officers and directors in their FINRA questionnaire to Representative
Counsel specifically for use by Representative Counsel in connection with its Public Offering System filings (and related disclosure)
with FINRA is true, correct and complete in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.21 <U>Foreign Corrupt Practices
Act</U>. None of the Company or, to the Company&#8217;s knowledge, any director, officer, agent, employee or affiliate of the Company
or any other person acting on behalf of the Company, has, directly or indirectly, given or agreed to give any money, gift or similar benefit
(other than legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a
customer or supplier, or official or employee of any governmental agency or instrumentality of any government (domestic or foreign) or
any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder
the business of the Company (or assist it in connection with any actual or proposed</P>


</div></center><!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">transaction) that (i) might subject the Company to
any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a
Material Adverse Change; (iii) if not continued in the future, might adversely affect the assets, business, operations or prospects of
the Company; (iv) violated or is in violation of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or regulation;
(v) made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment; or (vi) received notice of any investigation,
proceeding or inquiry by any Governmental Entity regarding any of the matters in clauses (i)-(v) above; and the Company and, to the knowledge
of the Company, the Company&#8217;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted
and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance
therewith. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company
to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder
(collectively, the &#8220;FCPA&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.22 <U>Compliance with OFAC</U>.
None of the Company or, to the Company&#8217;s knowledge, any director, officer, agent, employee or affiliate of the Company or any other
person acting on behalf of the Company, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control
of the U.S. Department of the Treasury (&#8220;OFAC&#8221;), and the Company will not, directly or indirectly, use the proceeds of the
Offering hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person
or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.23 <U>Forward-Looking Statements.</U>
No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in
either the Registration Statement, Disclosure Package or Prospectus has been made or reaffirmed without a reasonable basis or has been
disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.24 <U>Money Laundering Laws</U>.
The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting
requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions,
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by
any Governmental Entity (collectively, the &#8220;Money Laundering Laws&#8221;); and no action, suit or proceeding by or before any Governmental
Entity involving the Company with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.25 <U>Officers&#8217;
Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to you or to Representative Counsel
shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.26 <U>Lock-Up Agreements. Schedule
3</U> hereto contains a complete and accurate list of the Company&#8217;s officers, directors and each owner of at least 5% of the Company&#8217;s
outstanding shares of Common Stock, other than Steve Gorlin (or securities convertible or exercisable into shares of Common Stock) (collectively,
the &#8220;Lock-Up Parties&#8221;). The Company has caused each of the Lock-Up Parties to deliver to the Representative an executed Lock-Up
Agreement, in the form attached hereto as <U>Exhibit A</U> (the &#8220;Lock-Up Agreement&#8221;), prior to the execution of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.27 <U>Subsidiaries</U>. The
Company has no subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.28 <U>Related Party Transactions</U>.
There are no business relationships or related party transactions involving the Company or any other person required to be described in
the Registration Statement, the Disclosure Package and the Prospectus that have not been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.29 <U>Board of Directors</U>.
The Board of Directors of the Company is comprised of the persons disclosed in the Registration Statement, the Disclosure Package and
the Prospectus. The qualifications of the persons serving as board members and the overall composition of the board comply with the Exchange
Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the &#8220;Sarbanes-Oxley Act&#8221;)
applicable to the Company and the listing rules of the Exchange. At least one member of the Audit Committee of the</P>


</div></center><!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Board of Directors of the Company qualifies as an
&#8220;audit committee financial expert,&#8221; as such term is defined under Regulation S-K and the listing rules of the Exchange. In
addition, at least a majority of the persons serving on the Board of Directors qualify as &#8220;independent,&#8221; as defined under
the listing rules of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.30 <U>Sarbanes-Oxley Compliance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.30.1. <U>Disclosure Controls</U>.
The Company has developed and currently maintains disclosure controls and procedures that comply with Rule 13a-15 or 15d-15 under the
Exchange Act Regulations, and except as described in the Registration Statement, the Disclosure Package and the Prospectus, such controls
and procedures are effective to ensure that all material information concerning the Company is made known on a timely basis to the individuals
responsible for the preparation of the Company&#8217;s Exchange Act filings and other public disclosure documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">2.30.2. <U>Compliance</U>. The Company
is, or at the Applicable Time and on the Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley Act applicable
to it, and has implemented or will implement such programs and taken reasonable steps to ensure the Company&#8217;s future compliance
(not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions of the Sarbanes-Oxley Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.31 <U>Accounting Controls</U>.
The Company maintains systems of &#8220;internal control over financial reporting&#8221; (as defined under Rules 13a-15 and 15d-15 under
the Exchange Act Regulations) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision
of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions
are executed in accordance with management&#8217;s general or specific authorizations; (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted
only in accordance with management&#8217;s general or specific authorization; and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed
in the Registration Statement, the Disclosure Package and the Prospectus, the Company is not aware of any material weaknesses in its internal
controls. The Company&#8217;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all
significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are known
to the Company&#8217;s management and that have adversely affected or are reasonably likely to adversely affect the Company&#8217; ability
to record, process, summarize and report financial information; and (ii) any fraud known to the Company&#8217;s management, whether or
not material, that involves management or other employees who have a significant role in the Company&#8217;s internal controls over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.32 <U>No Investment Company
Status</U>. The Company is not and, after giving effect to the Offering and the application of the proceeds thereof as described in the
Registration Statement, the Disclosure Package and the Prospectus, will not be, required to register as an &#8220;investment company,&#8221;
as defined in the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.33 <U>No Labor Disputes</U>.
No labor dispute with the employees of the Company exists or, to the knowledge of the Company, is imminent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.34 <U>Intellectual Property
Rights</U>. The Company owns or possesses or has valid rights to use all patents, patent applications, trademarks, service marks, trade
names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets and similar rights (&#8220;Intellectual
Property Rights&#8221;) necessary for the conduct of the business of the Company as currently carried on and as described in the Registration
Statement, the Disclosure Package and the Prospectus. To the knowledge of the Company, no action or use by the Company necessary for the
conduct of its business as currently carried on and as described in the Registration Statement and the Prospectus will involve or give
rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of others. The Company has not received
any notice alleging any such infringement, fee or conflict with asserted Intellectual Property Rights of others. Except as would not reasonably
be expected to result, individually or in the aggregate, in a Material Adverse Change (A) to the knowledge of the Company, there is no</P>


</div></center><!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">infringement, misappropriation or violation by third
parties of any of the Intellectual Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company,
threatened action, suit, proceeding or claim by others challenging the rights of the Company in or to any such Intellectual Property Rights,
and the Company is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate,
together with any other claims in this Section 2.34, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual
Property Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have
not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the
Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual
Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would, individually
or in the aggregate, together with any other claims in this Section 2.34, reasonably be expected to result in a Material Adverse Change;
(D) there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others that the Company
infringes, misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company has
not received any written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any
such claim that would, individually or in the aggregate, together with any other claims in this Section 2.34, reasonably be expected to
result in a Material Adverse Change; and (E) to the Company&#8217;s knowledge, no employee of the Company is in or has ever been in violation
in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis
of such violation relates to such employee&#8217;s employment with the Company, or actions undertaken by the employee while employed with
the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the Company&#8217;s
knowledge, all material technical information developed by and belonging to the Company which has not been patented has been kept confidential.
The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any
other person or entity that are required to be set forth in the Registration Statement, the Disclosure Package and the Prospectus and
are not described therein. The Registration Statement, the Disclosure Package and the Prospectus contain in all material respects the
same description of the matters set forth in the preceding sentence. None of the technology employed by the Company has been obtained
or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Company&#8217;s knowledge,
any of its officers, directors or employees, or otherwise in violation of the rights of any persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.35 <U>Taxes</U><B>.</B> The Company has filed all
returns (as hereinafter defined) required to be filed with taxing authorities prior to the date hereof or has duly obtained extensions
of time for the filing thereof. The Company has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and
has paid all taxes imposed on or assessed against the Company. The provisions for taxes payable, if any, shown on the financial statements
filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for
all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriters,
(i) no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted
as due from the Company, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given
by or requested from the Company. The term &#8220;taxes&#8221; means all federal, state, local, foreign and other net income, gross income,
gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment,
excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments or charges
of any kind whatever, together with any interest and any penalties, additions to tax or additional amounts with respect thereto. The term
&#8220;returns&#8221; means all returns, declarations, reports, statements and other documents required to be filed in respect to taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.36 <U>ERISA Compliance</U>.
The Company and any &#8220;employee benefit plan&#8221; (as defined under the Employee Retirement Income Security Act of 1974, as amended,
and the regulations and published interpretations thereunder (collectively, &#8220;ERISA&#8221;)) established or maintained by the Company
or its &#8220;ERISA Affiliates&#8221; (as defined below) are in compliance in all material respects with ERISA. &#8220;ERISA Affiliate&#8221;
means, with respect to the Company, any member of any group of organizations described in Sections 414(b),(c),(m) or (o) of the Internal
Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#8220;Code&#8221;) of which the Company
is a member. No &#8220;reportable event&#8221; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to
any &#8220;employee benefit plan&#8221; established or maintained by the Company or any of its ERISA Affiliates.</P>


</div></center><!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No &#8220;employee benefit plan&#8221; established
or maintained by the Company or any of its ERISA Affiliates, if such &#8220;employee benefit plan&#8221; were terminated, would have any
&#8220;amount of unfunded benefit liabilities&#8221; (as defined under ERISA). None of the Company nor any of its ERISA Affiliates has
incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with respect to termination of, or withdrawal
from, any &#8220;employee benefit plan&#8221; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each &#8220;employee benefit plan&#8221;
established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code
is so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure to act, which would cause the
loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.37 <U>Compliance with Laws</U>.
The Company: (A) is and at all times has been in compliance with all statutes, rules, regulations, ordinances, judgments, orders and decrees
of all Governmental Entities applicable to the Company&#8217;s businesses (&#8220;Applicable Laws&#8221;), except as could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Change; (B) has not received any warning letter, untitled letter
or other correspondence or notice from any other Governmental Entity alleging or asserting noncompliance with any Applicable Laws or any
licenses, consents, certificates, approvals, clearances, authorizations, permits, orders and supplements or amendments thereto required
by any such Applicable Laws (&#8220;Authorizations&#8221;); (C) possesses all material Authorizations and such Authorizations are valid
and in full force and effect and are not in material violation of any term of any such Authorizations; (D) has not received notice of
any claim, action, suit, proceeding, hearing, enforcement, investigation, inquiry, arbitration or other action from any governmental authority
or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations and has no knowledge
that any such governmental authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation
or proceeding; (E) has not received notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend,
modify or revoke any Authorizations and has no knowledge that any such Governmental Entity is considering such action; (F) has filed,
obtained, maintained or submitted all material reports, documents, forms, filings, notices, applications, records, claims, submissions
and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected
or supplemented by a subsequent submission); and (G) has not, either voluntarily or involuntarily, initiated, conducted, or issued or
caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, &#8220;dear
doctor&#8221; letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product
defect or violation and, to the Company&#8217;s knowledge, no third party has initiated, conducted or intends to initiate any such notice
or action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.38 <U>Ineligible Issuer</U>.
At the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2)
of the Securities Act Regulations) of the Public Securities and at the date hereof, the Company was not and is not an &#8220;ineligible
issuer,&#8221; as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not
necessary that the Company be considered an ineligible issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.39 <U>Real Property</U>. Except
as set forth in the Registration Statement, the Disclosure Package and the Prospectus, the Company has good and marketable title in fee
simple to, or have valid rights to lease or otherwise use, all items of real or personal property which are material to the business of
the Company taken as a whole, in each case free and clear of all liens, encumbrances, security interests, claims and defects that do not,
singly or in the aggregate, materially affect the value of such property and do not interfere with the use made and proposed to be made
of such property by the Company; and all of the leases and subleases material to the business of the Company, and under which the Company
holds properties described in the Registration Statement, the Disclosure Package and the Prospectus, are in full force and effect, and
the Company has not received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the
Company under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company to the continued possession
of the leased or subleased premises under any such lease or sublease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.40 <U>Contracts Affecting Capital</U>.
There are no transactions, arrangements or other relationships between and/or among the Company, any of its affiliates (as such term is
defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including, but not limited to, any structured finance,
special purpose or limited purpose entity that could reasonably be expected to materially affect the Company&#8217;s liquidity or the
availability of or requirements for their capital resources required to be described or incorporated by reference in the</P>


</div></center><!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Registration Statement, the Disclosure Package and
the Prospectus which have not been described or incorporated by reference as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.41 <U>Loans to Directors or
Officers</U>. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business)
or guarantees of indebtedness by the Company to or for the benefit of any of the officers or directors of the Company, or any of their
respective family members, except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.42 <U>Smaller Reporting Company</U>.
As of the time of filing of the Registration Statement, the Company was a &#8220;smaller reporting company,&#8221; as defined in Rule
12b-2 of the Exchange Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.43 <U>Exchange Act Reports</U>.
The Company is subject to the requirement to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act and has filed all
reports and other materials required to be filed pursuant to Sections 13(a), 14 or 15(d) during the preceding 12 months. The Company has
filed in a timely manner all reports required to be filed pursuant to Sections 13(a), 13(e), 14 and 15(d) of the Exchange Act during the
preceding 12 months. The Company meets the registration requirements for use of Form S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.44 <U>Industry Data</U>. The
statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Disclosure Package
and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate
or represent the Company&#8217;s good faith estimates that are made on the basis of data derived from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.45 <U>Minute Books</U>. The
minute books of the Company have been made available to the Underwriters and Representative Counsel, and such books (i) contain a complete
summary of all meetings and actions of the board of directors (including each board committee) and stockholders of the Company (or analogous
governing bodies and interest holders, as applicable) since the time of its incorporation through the date of the latest meeting and action,
and (ii) accurately in all material respects reflect all transactions referred to in such minutes. There are no material transactions,
agreements, dispositions or other actions of the Company that are not properly approved and/or accurately and fairly recorded in the minute
books of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.46 <U>Integration</U>. Neither
the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers or sales
of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated with prior
offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.47 <U>No Stabilization</U>.
Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent of the Representative)
has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to
cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.48 <U>Confidentiality and Non-Competition.</U>
To the Company&#8217;s knowledge, no director, officer, key employee or consultant of the Company is subject to any confidentiality, non-disclosure,
non-competition agreement or non-solicitation agreement with any employer or prior employer that could reasonably be expected to materially
affect his ability to be and act in his respective capacity of the Company or be expected to result in a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.49 <U>Electronic Road Show</U>.
The Company can make available a Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii) of the Securities Act Regulations
such that no filing of any &#8220;road show&#8221; (as defined in Rule 433(h) of the Securities Act Regulations) is required in connection
with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.50 <U>Margin Securities</U>.
The Company owns no &#8220;margin securities&#8221; as that term is defined in Regulation U of the Board of Governors of the Federal Reserve
System (the &#8220;Federal Reserve Board&#8221;), and none of the proceeds of Offering will be used, directly or indirectly, for the purpose
of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred
to purchase or carry any margin</P>


</div></center><!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">security or for any other purpose which might cause
any of the shares of Common Stock to be considered a &#8220;purpose credit&#8221; within the meanings of Regulation T, U or X of the Federal
Reserve Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif">3.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><U>Covenants of the Company</U>. The Company covenants and agrees as follows:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1 <U>Amendments to Registration
Statement</U>. The Company shall deliver to the Representative, prior to filing, any amendment or supplement to the Registration Statement
or Prospectus proposed to be filed after the date hereof and not file any such amendment or supplement to which the Representative shall
reasonably object in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2 <U>Federal Securities Laws</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.2.1. <U>Compliance</U>. The Company,
subject to Section 3.2.2, shall comply with the requirements of Rule 430B of the Securities Act Regulations, and will notify the Representative
promptly, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall become effective
or any amendment or supplement to the Prospectus shall have been filed; (ii) of the receipt of any comments from the Commission; (iii)
of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or for
additional information; (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement
or any post-effective amendment or of any order preventing or suspending the use of any Preliminary Prospectus or the Prospectus, or of
the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction, or of the initiation or threatening
of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the
Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection
with the Offering of the Public Securities. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations,
in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it
deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing
by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company shall use its best efforts to
prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the
earliest possible moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.2.2. <U>Continued Compliance</U>.
The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange Act Regulations so
as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and in the Registration Statement,
the Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public Securities is (or, but for the exception
afforded by Rule 172 of the Securities Act Regulations (&#8220;Rule 172&#8221;), would be) required by the Securities Act to be delivered
in connection with sales of the Public Securities, any event shall occur or condition shall exist as a result of which it is necessary,
in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement in order that the Registration
Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading; (ii) amend or supplement the Disclosure Package or the Prospectus in order that the Disclosure
Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered
to a purchaser or (iii) amend the Registration Statement or amend or supplement the Disclosure Package or the Prospectus, as the case
may be, in order to comply with the requirements of the Securities Act or the Securities Act Regulations, the Company will promptly (A)
give the Representative notice of such event; (B) prepare any amendment or supplement as may be necessary to correct such statement or
omission or to make the Registration Statement, the Disclosure Package or the Prospectus comply with such requirements and, a reasonable
amount of time prior to any proposed filing or use, furnish the Representative with copies of any such amendment or supplement and (C)
file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement
to which the Representative or counsel for the Underwriters shall reasonably object. The Company will furnish to the Underwriters such
number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representative
notice of any filings made pursuant to the Exchange Act or the Exchange Act Regulations within 48 hours prior to the Applicable Time.
The Company shall give the Representative notice of its intention to make any such filing from the Applicable Time until the later of
the Closing</P>


</div></center><!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date and the exercise in full or expiration of the
Over-allotment Option specified in Section 1.2 and will furnish the Representative with copies of the related document(s) a reasonable
amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative
or counsel for the Underwriters shall reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.2.3. <U>Exchange Act Registration</U>.
For a period of three (3) years after the date of this Agreement, the Company shall use its best efforts to maintain the registration
of the shares of Common Stock under the Exchange Act. The Company shall not deregister the shares of Common Stock under the Exchange Act
without the prior written consent of the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.2.4. <U>Free Writing Prospectuses</U>.
The Company agrees that, unless it obtains the prior written consent of the Representative, it shall not make any offer relating to the
Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#8220;free writing prospectus,&#8221;
or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that
the Representative shall be deemed to have consented to each Issuer General Use Free Writing Prospectus hereto and any &#8220;road show
that is a written communication&#8221; within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representative. The Company
represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by
the Underwriters as an &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433, and that it has complied and will comply
with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending
and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development
as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration
Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company
will promptly notify the Underwriters and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to
eliminate or correct such conflict, untrue statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.3 <U>Delivery to the Underwriters
of Registration Statements</U>. The Company has delivered or made available or shall deliver or make available to the Representative and
counsel for the Representative, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto
(including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed to be incorporated by reference
therein) and signed copies of all consents and certificates of experts, and will also deliver to the Underwriters, without charge, a conformed
copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The
copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.4 <U>Delivery to the Underwriters
of Prospectuses</U>. The Company has delivered or made available or will deliver or make available to each Underwriter, without charge,
as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of
such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter, without charge, during the period
when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered
under the Securities Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request.
The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted
copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.5 <U>Effectiveness and Events
Requiring Notice to the Representative</U>. The Company shall use its best efforts to cause the Registration Statement to remain effective
with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representative immediately and
confirm the notice in writing: (i) of the effectiveness of the Registration Statement and any amendment thereto; (ii) of the issuance
by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii) of the issuance
by any state securities commission of any proceedings for the suspension of the qualification of the Public Securities for offering or
sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv) of the mailing and delivery
to the Commission for filing of any amendment or supplement to the Registration</P>


</div></center><!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Statement or Prospectus; (v) of the receipt of any
comments or request for any additional information from the Commission; and (vi) of the happening of any event during the period described
in this Section 3.5 that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement, the
Disclosure Package or the Prospectus untrue or that requires the making of any changes in (a) the Registration Statement in order to make
the statements therein not misleading, or (b) in the Disclosure Package or the Prospectus in order to make the statements therein, in
light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission shall enter
a stop order or suspend such qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting
of such order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.6 <U>Review of Financial Statements.</U>
For a period of five (5) years after the date of this Agreement, the Company, at its expense, shall cause its regularly engaged independent
registered public accounting firm to review (but not audit) the Company&#8217;s financial statements for each of the three fiscal quarters
immediately preceding the announcement of any quarterly financial information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.7 <U>Listing</U>. The Company
shall use its commercially reasonable efforts to maintain the listing of the shares of Common Stock (including the Public Securities)
on the Exchange for at least three years from the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.8 <U>Intentionally Omitted.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.9 <U>Reports to the Representative</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.9.1. <U>Periodic Reports, etc</U>.
For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available to the Representative copies
of such financial statements and other periodic and special reports as the Company from time to time furnishes generally to holders of
any class of its securities and also promptly furnish to the Representative: (i) a copy of each periodic report the Company shall be required
to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press release and every news
item and article with respect to the Company or its affairs which was released by the Company; (iii) a copy of each Form 8-K prepared
and filed by the Company; (iv) five copies of each registration statement filed by the Company under the Securities Act; and (v) a copy
of each report or other communication furnished to stockholders; and (vi) such additional documents and information with respect to the
Company and the affairs of any future subsidiaries of the Company as the Representative may from time to time reasonably request; provided
the Representative shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which is reasonably acceptable
to the Representative and Representative Counsel in connection with the Representative&#8217;s receipt of such information. Documents
filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered to the Representative pursuant to this Section
3.9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.9.2. <U>Transfer Agent; Transfer
Sheets</U>. For a period of one (1) year after the date of this Agreement, the Company shall continue to retain a transfer agent and registrar
acceptable to the Representative (the &#8220;Transfer Agent&#8221;) and shall furnish to the Representative at the Company&#8217;s sole
cost and expense such transfer sheets of the Company&#8217;s securities as the Representative may reasonably request, including the daily
and monthly consolidated transfer sheets of the Transfer Agent and DTC. West Coast Stock Transfer, Inc. is acceptable to the Representative
to act as Transfer Agent for the shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.9.3. <U>Trading Reports</U>. During
a period of one (1) year after the date of this Agreement, the Company shall provide to the Representative, at the Company&#8217;s expense,
such reports published by Exchange relating to price trading of the shares of Common Stock (including the Firm Shares), as the Representative
shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.10 <U>Payment of Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">3.10.1. <U>General Expenses Related to the Offering</U>.
The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date, if any, to the extent not paid at the Closing
Date, all expenses incident to the performance of the obligations of the Company under this Agreement, including, but not limited to:
(a) all filing fees and communication expenses relating to the registration of the Public Securities with the Commission; (b) all Public
Filing System filing fees associated with the review of the Offering by FINRA; (c) all</P>


</div></center><!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">fees and expenses relating to the listing of such Public Securities on
the Exchange and such other stock exchanges as the Company and the Representative together determine; (d) all fees, expenses and disbursements
relating to background checks of the Company&#8217;s officers and directors in an amount not to exceed $15,000 in the aggregate; (e) all
fees, expenses and disbursements relating to the registration or qualification of the Public Securities under the &#8220;blue sky&#8221;
securities laws of such states and other jurisdictions as the Representative may reasonably designate; (f) all fees, expenses and disbursements
relating to the registration, qualification or exemption of the Public Securities under the securities laws of such foreign jurisdictions
as the Representative may reasonably designate; (g) the costs of all mailing and printing of the underwriting documents (including, without
limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters, Selected Dealers&#8217;
Agreement, Underwriters&#8217; Questionnaire and Power of Attorney), Registration Statements, Prospectuses and all amendments, supplements
and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably deem necessary; (h) the costs
and expenses of a public relations firm; (i) the costs of preparing, printing and delivering certificates representing the Public Securities;
(j) fees and expenses of the transfer agent for the shares of Common Stock; (k) stock transfer and/or stamp taxes, if any, payable upon
the transfer of securities from the Company to the Underwriters; (l) to the extent approved by the Company in writing the costs associated
with post-Closing advertising the Offering in the national editions of the Wall Street Journal and New York Times; (m) the costs associated
with one set of bound volumes of the public offering materials as well as commemorative mementos and lucite tombstones, each of which
the Company or its designee shall provide within a reasonable time after the Closing Date in such quantities as the Representative may
reasonably request; (n) the fees and expenses of the Company&#8217;s accountants; (o) the fees and expenses of the Company&#8217;s legal
counsel and other agents and representatives; (p) fees and expenses of the Representative&#8217;s legal counsel not to exceed $125,000;
(q) the $29,500 cost associated with the Underwriter&#8217;s use of Ipreo&#8217;s book-building, prospectus tracking and compliance software
for the Offering; (r) $10,000 for data services and communications expenses; (s) up to $10,000 of the Representative&#8217;s actual accountable
&#8220;road show&#8221; expenses. The Representative may deduct from the net proceeds of the Offering payable to the Company on the Closing
Date the expenses set forth herein to be paid by the Company to the Underwriters from the flow of funds relating to such Closing Date
or Option Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">3.10.2. <FONT STYLE="font-size: 11pt"><U>Non-accountable
Expenses</U>. The Company further agrees that, in addition to the expenses payable pursuant to Section 3.10.1, on the Closing Date it
shall pay to the Representative through the flow of funds memo at Closing, by deduction from the net proceeds of the Offering contemplated
herein, a non-accountable expense allowance equal to one percent (1%) of the gross proceeds received by the Company from the sale of the
Firm Shares (excluding the Option Shares), provided, however, that in the event that the Offering is terminated, the Company agrees to
reimburse the Underwriters pursuant to Section 8.3 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.11 <U>Application of
Net Proceeds</U>. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the application
thereof described under the caption &#8220;Use of Proceeds&#8221; in the Registration Statement, the Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.12 <U>Delivery of Earnings Statements
to Security Holders</U>. The Company shall make generally available to its security holders as soon as practicable, but not later than
the first day of the fifteenth (15<FONT STYLE="font-size: 12.5pt"><SUP>th</SUP></FONT>) full calendar month following the date of this
Agreement, an earnings statement (which need not be certified by independent registered public accounting firm unless required by the
Securities Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities
Act) covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.13 <U>Stabilization</U>. Neither
the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent of the Representative) has taken
or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or
result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.14 <U>Internal Controls</U>.
The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions
are executed in accordance with management&#8217;s general or specific authorization; (ii) transactions are recorded as necessary in order
to permit preparation of financial</P>


</div></center><!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">statements in accordance with GAAP and to maintain
accountability for assets; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization;
and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken
with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.15 <U>Accountants</U>. The Company
shall continue to retain a nationally recognized independent registered public accounting firm for a period of at least three (3) years
after the date of this Agreement. The Representative acknowledges that the Auditor is acceptable to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.16 <U>FINRA</U>. The Company
shall advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i) any officer or director
of the Company, or (ii) any beneficial owner of 5% or more of any class of the Company&#8217;s equity and equity-linked securities is
or becomes an affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules
and regulations of FINRA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.17 <U>No Fiduciary Duties</U>.
The Company acknowledges and agrees that the Underwriters&#8217; responsibility to the Company is solely contractual in nature and that
none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity, or otherwise owes
any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions contemplated by
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.18 <U>Company Lock-Up Agreements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.18.1. <U>Restriction on Sales
of Capital Stock</U>. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the
Representative, it will not, for a period of two (2) months after the date of this Agreement (the &#8220;Lock-Up Period&#8221;), (i) offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company
or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or cause to be
filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities
convertible into or exercisable or exchangeable for shares of capital stock of the Company; (iii) complete any offering of debt securities
of the Company, other than entering into a line of credit with a traditional bank or (iv) enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any
such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company
or such other securities, in cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">The restrictions contained in this
Section 3.18.1 shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the issuance by the Company of shares of Common
Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding on the date hereof, which is disclosed
in the Registration Statement, Disclosure Package and Prospectus, provided that such options, warrants, and securities have not been amended
since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion
price of such securities or to extend the term of such securities, or (iii) the issuance by the Company of stock options or shares of
capital stock of the Company under any equity compensation plan of the Company, provided that in each of (ii) and (iii) above, the underlying
shares shall be restricted from sale during the entire Lock-Up Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">3.18.2. <U>Restriction on Continuous
Offerings</U>. Notwithstanding the restrictions contained in Section 3.18.1, the Company, on behalf of itself and any successor entity,
agrees that, without the prior written consent of the Representative, it will not, for a period of twelve (12) months after the date of
this Agreement, directly or indirectly in any &#8220;at-the-market,&#8221; continuous equity or variable rate transaction, offer to sell,
sell, contract to sell, grant any option to sell or otherwise dispose of shares of capital stock of the Company or any securities convertible
into or exercisable or exchangeable for shares of capital stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.19 <U>Blue Sky Qualifications</U>.
The Company shall use its best efforts, in cooperation with the Underwriters, if necessary, to qualify the Public Securities for offering
and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representative may designate
and to maintain such qualifications</P>


</div></center><!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">in effect so long as required to complete the distribution
of the Public Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process
or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject
itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.20 <U>Reporting Requirements</U>.
The Company, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172,
would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission pursuant
to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally, the Company shall
report the use of proceeds from the issuance of the Public Securities as may be required under Rule 463 under the Securities Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. <U>Conditions of Underwriters&#8217; Obligations</U>.
The obligations of the Underwriters to purchase and pay for the Public Securities, as provided herein, shall be subject to (i) the continuing
accuracy of the representations and warranties of the Company as of the date hereof and as of the Closing Date; (ii) the accuracy of the
statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations
hereunder; and (iv) the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1 <U>Regulatory Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.1.1. <U>Commission Actions; Required
Filings</U>. At the Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus
has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&#8217;s knowledge,
contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. The
Prospectus containing the Rule 430B Information shall have been filed with the Commission in the manner and within the time frame required
by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with,
and declared effective by, the Commission in accordance with the requirements of Rule 430B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.1.2. <U>Exchange Stock Market
Clearance</U>. On the Closing Date, the Firm Shares shall have been approved for listing on the Exchange, subject only to official notice
of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2 <U>Company Counsel Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.1. <U>Closing Date Opinion of
Counsel</U>. On the Closing Date, the Representative shall have received the favorable opinions of (i) Loeb &amp; Loeb LLP, counsel to
the Company, and a written statement providing certain &#8220;10b-5&#8221; negative assurances, (ii) Sherman &amp; Howard L.L.C., counsel
to the Company with respect to certain matters of Nevada law, (iii) Knobbe, Martens, Olson &amp; Bear, LLP, counsel to the Company with
respect to certain intellectual property matters and (iv) McDonnell, Boehnen, Hulbert &amp; Berghoff LLP, counsel to the Company with
respect to certain intellectual property matters, each dated the Closing Date and addressed to the Representative, in form and substance
satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.2. <U>Option Closing Date Opinions
of Counsel</U>. On the Option Closing Date, if any, the Representative shall have received the favorable opinions of each counsel listed
in Section 4.2.1, dated the Option Closing Date, addressed to the Representative and in form and substance reasonably satisfactory to
the Representative, confirming as of the Option Closing Date, the statements made by such counsels in their respective opinions delivered
on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.2.3. <U>Reliance</U>. In rendering
such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the laws of the United States and
jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified in such opinion, if at all,
upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of other counsel reasonably acceptable
to the Representative, familiar with the applicable laws; and (ii) as to matters of fact, to the extent they deem proper, on certificates
or other written statements of officers of the Company and officers of departments of various jurisdictions having custody of documents
respecting the corporate existence or good standing of the Company,</P>


</div></center><!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">provided that copies of any such statements or certificates
shall be delivered to Representative Counsel if requested. The opinions of Loeb &amp; Loeb LLP, Sherman &amp; Howard L.L.C., Knobbe, Martens,
Olson &amp; Bear, LLP, McDonnell, Boehnen, Hulbert &amp; Berghoff LLP, and any opinion relied upon by such counsel shall include a statement
to the effect that it may be relied upon by Representative Counsel in its opinion delivered to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.3 <U>Comfort Letter</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.3.1. <U>Cold Comfort Letter</U>.
At the Closing Date, you shall have received a cold comfort letter containing statements and information of the type customarily included
in accountants&#8217; comfort letters with respect to the financial statements and certain financial information contained or incorporated
or deemed incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus, addressed to the Representative
and in form and substance satisfactory in all respects to you and to the Auditor, dated as of the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.4 <U>Officers&#8217; Certificates</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.4.1. <U>Officers&#8217; Certificate</U>.
The Company shall have furnished to the Representative a certificate, dated the Closing Date and any Option Closing Date (if such date
is other than the Closing Date), of its Chief Executive Officer, its President and its Chief Financial Officer stating that (i) such officers
have carefully examined the Registration Statement, the Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and,
in their opinion, the Registration Statement and each amendment thereto, as of the Applicable Time and as of the Closing Date (or any
Option Closing Date if such date is other than the Closing Date) did not include any untrue statement of a material fact and did not omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and the Disclosure
Package, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date),
any Issuer Free Writing Prospectus as of its date and as of the Closing Date (or any Option Closing Date if such date is other than the
Closing Date), the Prospectus and each amendment or supplement thereto, as of the respective date thereof and as of the Closing Date (or
any Option Closing Date if such date is other than the Closing Date), did not include any untrue statement of a material fact and did
not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances in which they were
made, not misleading, (ii) since the effective date of the Registration Statement, no event has occurred which should have been set forth
in a supplement or amendment to the Registration Statement, the Disclosure Package or the Prospectus, (iii) to their knowledge, as of
the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the representations and warranties of the Company
in this Agreement are true and correct and the Company has complied with all agreements and satisfied all conditions on its part to be
performed or satisfied hereunder at or prior to the Closing Date (or any Option Closing Date if such date is other than the Closing Date)
, and (iv) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference
in the Disclosure Package, any material adverse change in the financial position or results of operations of the Company, or any change
or development that, singularly or in the aggregate, would involve a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.4.2. <U>Secretary&#8217;s Certificate</U>.
At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received a certificate of the Company signed
by the Secretary of the Company, dated the Closing Date or the Option Closing Date, as the case may be, respectively, certifying: (i)
that each of the Charter and By-laws is true and complete, has not been modified and is in full force and effect; (ii) that the resolutions
of the Company&#8217;s Board of Directors relating to the Offering are in full force and effect and have not been modified; (iii) as to
the accuracy and completeness of all correspondence between the Company or its counsel and the Commission; and (iv) as to the incumbency
of the officers of the Company. The documents referred to in such certificate shall be attached to such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">4.4.3. <U>CFO Certificate</U>. At the each of Closing
Date and the Option Closing Date, if any, the Representative shall have received a certificate of the Company signed by the Chief Financial
Officer of the Company, dated the Closing Date or the Option Closing Date, as the case may be, respectively, certifying certain financial
information contained or incorporated or deemed incorporated by reference in the Registration Statement, the Disclosure Package and the
Prospectus, in form and substance satisfactory in all respects to the Representative. The documents referred to in such certificate shall
be attached to such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>


</div></center><!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.5 <U>No Material Changes</U>.
Prior to and on the Closing Date: (i) there shall have been no material adverse change or development involving a prospective material
adverse change in the condition or prospects or the business activities, financial or otherwise, of the Company from the latest dates
as of which such condition is set forth in the Registration Statement, the Disclosure Package and the Prospectus; (ii) no action, suit
or proceeding, at law or in equity, shall have been pending or threatened against the Company or any Insider before or by any court or
federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding may materially adversely
affect the business, operations, properties, assets, prospects or financial condition or income of the Company, except as set forth in
the Registration Statement, the Disclosure Package and the Prospectus; (iii) no stop order shall have been issued under the Securities
Act and no proceedings therefor shall have been initiated or threatened by the Commission; and (iv) the Registration Statement, the Disclosure
Package and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated
therein in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements
of the Securities Act and the Securities Act Regulations, and neither the Registration Statement, the Disclosure Package nor the Prospectus
nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.6 <U>Corporate Proceedings.</U>
All corporate proceedings and other legal matters incident to the authorization, form and validity of each of this Agreement, the Public
Securities, the Registration Statement, the Disclosure Package and the Prospectus and all other legal matters relating to this Agreement
and the transactions contemplated hereby and thereby shall be reasonably satisfactory in all material respects to counsel for the Underwriters,
and the Company shall have furnished to such counsel all documents and information that they may reasonably request to enable them to
pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.7 <U>Delivery of Agreements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">4.7.1. <U>Lock-Up Agreements</U>.
On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies of the Lock-Up Agreements
from each of the persons listed in <U>Schedule 3</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.8 <U>Additional Documents</U>.
At the Closing Date, Representative Counsel shall have been furnished with such documents and opinions as they may require for the purpose
of enabling Representative Counsel to deliver an opinion to the Underwriters, or in order to evidence the accuracy of any of the representations
or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with
the issuance and sale of the Public Securities as herein contemplated shall be satisfactory in form and substance to the Representative
and Representative Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif">5.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><U>Indemnification</U>.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1 <U>Indemnification of the
Underwriters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">5.1.1. <U>General</U>. Subject to
the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates and each of its and
their respective directors, officers, members, employees, representatives, partners, stockholders, affiliates, counsel, and agents and
each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act (collectively the &#8220;Underwriter Indemnified Parties,&#8221; and each an &#8220;Underwriter Indemnified Party&#8221;), against
any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all legal or other expenses reasonably
incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising
out of any action between any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties
and any third party, or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other
statute or at common law or otherwise or under the laws of foreign countries (a &#8220;Claim&#8221;), (i) arising out of or based upon
any untrue statement or alleged untrue statement of a material fact contained in (A) the Registration Statement, the Disclosure Package,
any Preliminary Prospectus, the Prospectus, or in any Issuer Free Writing Prospectus or in any Written Testing-the-Waters Communication
(as from time to time each may be amended and supplemented); (B) any materials or information provided to investors by, or with the approval
of, the Company in connection with the</P>


</div></center><!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">marketing of the Offering, including any &#8220;road
show&#8221; or investor presentations made to investors by the Company (whether in person or electronically); or (C) any application or
other document or written communication (in this Section 5, collectively called &#8220;application&#8221;) executed by the Company or
based upon written information furnished by the Company in any jurisdiction in order to qualify the Public Securities under the securities
laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or any other national securities exchange;
or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon,
and in conformity with, the Underwriters&#8217; Information or (ii) otherwise arising in connection with or allegedly in connection with
the Offering. The Company also agrees that it will reimburse each Underwriter Indemnified Party for all fees and expenses (including but
not limited to any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation,
commenced or threatened, or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties
and the Company or between any of the Underwriter Indemnified Parties and any third party, or otherwise) (collectively, the &#8220;Expenses&#8221;),
and further agrees wherever and whenever possible to advance payment of Expenses as they are incurred by an Underwriter Indemnified Party
in investigating, preparing, pursuing or defending any Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">5.1.2. <U>Procedure</U>. If any
action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against the Company pursuant to
Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company in writing of the institution of such action and the
Company shall assume the defense of such action, including the employment and fees of counsel (subject to the approval of such Underwriter
Indemnified Party) and payment of actual expenses if an Underwriter Indemnified Party requests that the Company do so. Such Underwriter
Indemnified Party shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel
shall be at the expense of the Company, and shall be advanced by the Company. The Company shall not be liable for any settlement of any
action effected without its consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior
written consent of the Underwriters, settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate any
pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution may be sought hereunder (whether
or not such Underwriter Indemnified Party is a party thereto) unless such settlement, compromise, consent or termination (i) includes
an unconditional release of each Underwriter Indemnified Party, acceptable to such Underwriter Indemnified Party, from all liabilities,
expenses and claims arising out of such action for which indemnification or contribution may be sought and (ii) does not include a statement
as to or an admission of fault, culpability or a failure to act, by or on behalf of any Underwriter Indemnified Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2 <U>Indemnification of the
Company</U>. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors, its officers
who signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company
to the several Underwriters, as incurred, but only with respect to untrue statements or omissions made in the Registration Statement,
any Preliminary Prospectus, the Disclosure Package or Prospectus or any amendment or supplement thereto or in any application, in reliance
upon, and in strict conformity with, the Underwriters&#8217; Information. In case any action shall be brought against the Company or any
other person so indemnified based on any Preliminary Prospectus, the Registration Statement, the Disclosure Package or Prospectus or any
amendment or supplement thereto or any application, and in respect of which indemnity may be sought against any Underwriter, such Underwriter
shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have the rights and
duties given to the several Underwriters by the provisions of Section 5.1.2. The Company agrees promptly to notify the Representative
of the commencement of any litigation or proceedings against the Company or any of its officers, directors or any person, if any, who
controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection with the
issuance and sale of the Public Securities or in connection with the Registration Statement, the Disclosure Package, the Prospectus, or
any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3 <U>Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">5.3.1. <U>Contribution Rights</U>.
If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to hold harmless an indemnified
party under Section 5.1 or 5.2 in respect of</P>


</div></center><!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">any loss, claim, damage or liability, or any action
in respect thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute
to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof,
(i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters,
on the other, from the Offering of the Public Securities, or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative
fault of the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions that resulted in
such loss, claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations. The relative
benefits received by the Company, on the one hand, and the Underwriters, on the other, with respect to such Offering shall be deemed to
be in the same proportion as the total net proceeds from the Offering of the Public Securities purchased under this Agreement (before
deducting expenses) received by the Company, as set forth in the table on the cover page of the Prospectus, on the one hand, and the total
underwriting discounts and commissions received by the Underwriters with respect to the shares of the Common Stock purchased under this
Agreement, as set forth in the table on the cover page of the Prospectus, on the other hand. The relative fault shall be determined by
reference to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact
relates to information supplied by the Company or the Underwriters, the intent of the parties and their relative knowledge, access to
information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not
be just and equitable if contributions pursuant to this Section 5.3.1 were to be determined by pro rata allocation (even if the Underwriters
were treated as one entity for such purpose) or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action
in respect thereof, referred to above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1, any legal
or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 5.3.1 in no event shall an Underwriter be required to contribute any amount in excess of
the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the Offering of the
Public Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">5.3.2. <U>Contribution Procedure</U>.
Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement of any action,
suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party (&#8220;contributing
party&#8221;), notify the contributing party of the commencement thereof, but the failure to so notify the contributing party will not
relieve it from any liability which it may have to any other party other than for contribution hereunder. In case any such action, suit
or proceeding is brought against any party, and such party notifies a contributing party or its representative of the commencement thereof
within the aforesaid 15 days, the contributing party will be entitled to participate therein with the notifying party and any other contributing
party similarly notified. Any such contributing party shall not be liable to any party seeking contribution on account of any settlement
of any claim, action or proceeding affected by such party seeking contribution on account of any settlement of any claim, action or proceeding
affected by such party seeking contribution without the written consent of such contributing party. The contribution provisions contained
in this Section 5.3.2 are intended to supersede, to the extent permitted by law, any right to contribution under the Securities Act, the
Exchange Act or otherwise available. Each Underwriter&#8217;s obligations to contribute pursuant to this Section 5.3 are several and not
joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif">6.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><U>Default by an Underwriter</U>.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.1 <U>Default Not Exceeding 10%
of Firm Shares or Option Shares</U>. If any Underwriter or Underwriters shall default in its or their obligations to purchase the Firm
Shares or the Option Shares, if the Over-allotment Option is exercised hereunder, and if the number of the Firm Shares or Option Shares
with respect to which such default relates does not exceed in the aggregate 10% of the number of Firm Shares or Option Shares that all
Underwriters have agreed to purchase hereunder, then such Firm Shares or Option Shares to which the default relates shall be purchased
by the non-defaulting Underwriters in proportion to their respective commitments hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


</div></center><!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.2 <U>Default Exceeding 10% of
Firm Shares or Option Shares</U>. In the event that the default addressed in Section 6.1 relates to more than 10% of the Firm Shares or
Option Shares, you may in your discretion arrange for yourself or for another party or parties to purchase such Firm Shares or Option
Shares to which such default relates on the terms contained herein. If, within one (1) Business Day after such default relating to more
than 10% of the Firm Shares or Option Shares, you do not arrange for the purchase of such Firm Shares or Option Shares, then the Company
shall be entitled to a further period of one (1) Business Day within which to procure another party or parties satisfactory to you to
purchase said Firm Shares or Option Shares on such terms. In the event that neither you nor the Company arrange for the purchase of the
Firm Shares or Option Shares to which a default relates as provided in this Section 6, this Agreement will automatically be terminated
by you or the Company without liability on the part of the Company (except as provided in Sections 3.9 and 5 hereof) or the several Underwriters
(except as provided in Section 5 hereof); provided, however, that if such default occurs with respect to the Option Shares, this Agreement
will not terminate as to the Firm Shares; and provided, further, that nothing herein shall relieve a defaulting Underwriter of its liability,
if any, to the other Underwriters and to the Company for damages occasioned by its default hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">6.3 <U>Postponement of
Closing Date</U>. In the event that the Firm Shares or Option Shares to which the default relates are to be purchased by the non-defaulting
Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have the right to postpone the
Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days, in order to effect whatever changes may thereby
be made necessary in the Registration Statement, the Disclosure Package or the Prospectus or in any other documents and arrangements,
and the Company agrees to file promptly any amendment to the Registration Statement, the Disclosure Package or the Prospectus that in
the opinion of counsel for the Underwriter may thereby be made necessary. The term &#8220;Underwriter&#8221; as used in this Agreement
shall include any party substituted under this Section 6 with like effect as if it had originally been a party to this Agreement with
respect to such shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif">7.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><U>Additional Covenants</U>.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.1 <U>Board Composition and Board
Designations</U>. The Company shall ensure that: (i) the qualifications of the persons serving as members of the Board of Directors and
the overall composition of the Board comply with the Sarbanes-Oxley Act, with the Exchange Act and with the listing rules of the Exchange
or any other national securities exchange, as the case may be, in the event the Company seeks to have its Public Securities listed on
another exchange or quoted on an automated quotation system, and (ii) if applicable, at least one member of the Audit Committee of the
Board of Directors qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined under Regulation S-K and the
listing rules of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.2 <U>Prohibition on Press Releases
and Public Announcements</U>. The Company shall not issue press releases or engage in any other publicity, without the Representative&#8217;s
prior written consent, for a period ending at 5:00 p.m., Eastern time, on the first (1<FONT STYLE="font-size: 12.5pt"><SUP>st</SUP></FONT>)
Business Day following the forty-fifth (45<FONT STYLE="font-size: 12.5pt"><SUP>th</SUP></FONT>) day after the Closing Date, other than
normal and customary releases issued in the ordinary course of the Company&#8217;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif">8.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><U>Effective Date of this Agreement and Termination Thereof</U>.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.1 <U>Effective Date</U>. This
Agreement shall become effective when both the Company and the Representative have executed the same and delivered counterparts of such
signatures to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.2 <U>Termination</U>. The Representative
shall have the right to terminate this Agreement at any time prior to any Closing Date, (i) if any domestic or international event or
act or occurrence has materially disrupted, or in your opinion will in the immediate future materially disrupt, general securities markets
in the United States; or (ii) if trading on the New York Stock Exchange or the Nasdaq Stock Market LLC shall have been suspended or materially
limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required
by FINRA or by order of the Commission or any other government authority having jurisdiction; or (iii) if the United States shall have
become involved in a new war or an increase in major hostilities; or (iv) if a banking moratorium has been declared by a New York State
or federal authority; or (v) if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United
States securities markets; or (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane,</P>


</div></center><!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">earthquake, theft, sabotage or other calamity or malicious
act which, whether or not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery of
the Firm Shares; or (vii) if the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii)
if the Representative shall have become aware after the date hereof of such a material adverse change in the conditions or prospects of
the Company, or such adverse material change in general market conditions as in the Representative&#8217;s judgment would make it impracticable
to proceed with the offering, sale and/or delivery of the Public Securities or to enforce contracts made by the Underwriters for the sale
of the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.3 <U>Expenses</U>. Notwithstanding
anything to the contrary in this Agreement, in the event that this Agreement shall not be carried out for any reason whatsoever, within
the time specified herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters
their actual and accountable out-of-pocket expenses related to the transactions contemplated herein then due and payable (including the
fees and disbursements of Representative Counsel) up to $100,000 and upon demand the Company shall pay the full amount thereof to the
Representative on behalf of the Underwriters; provided, however, that such expense cap in no way limits or impairs the indemnification
and contribution provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.4 <U>Indemnification</U>. Notwithstanding
any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether or not this
Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force and effect and shall not be in any way affected
by, such election or termination or failure to carry out the terms of this Agreement or any part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.5 <U>Representations, Warranties,
Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement or in certificates of officers of
the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by
or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors
or any person controlling the Company or (ii) delivery of and payment for the Public Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 10pt Times New Roman, Times, Serif">9.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><U>Miscellaneous</U>.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">9.1 <U>Notices</U>. All communications hereunder, except as herein
otherwise specifically provided, shall be in writing and shall be mailed (registered or certified mail, return receipt requested), personally
delivered or sent by facsimile transmission and confirmed and shall be deemed given when so delivered or faxed and confirmed or if mailed,
two (2) days after such mailing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If to the Representative:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">ThinkEquity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">17 State Street, 22<FONT STYLE="font-size: 12.5pt"><SUP>nd</SUP></FONT>
Fl</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">New York, NY 10004<BR>
Attn: Mr. Eric Lord, Head of Investment Banking</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax: (212) 349-2550</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Sheppard, Mullin, Richter &amp; Hampton LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">30 Rockefeller Plaza</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">New York, NY 10112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Attention: Jeffrey J. Fessler, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No: (917) 438-6133</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">BioVie Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">2120 Colorado Avenue, Suite 230</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Santa Monica, CA 90404</P>


</div></center><!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Attention: Cuong V. Do</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No: (310) 444-4300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Loeb &amp; Loeb LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">345 Park Avenye</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">New York, NY 10154</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Attention: Mitchell Nussbaum, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No: (212) 407-4990</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.2 <U>Headings</U>. The headings
contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation
of any of the terms or provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.3 <U>Amendment</U>. This Agreement
may only be amended by a written instrument executed by each of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.4 <U>Entire Agreement</U>. This
Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this Agreement) constitutes
the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes all prior agreements
and understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding anything to the contrary
set forth herein, it is understood and agreed by the parties hereto that all other terms and conditions of that certain engagement letter
between the Company and ThinkEquity, a division of Fordham Financial Management, Inc., dated February 11, 2021, shall remain in full force
and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">9.5 <U>Binding Effect</U>.
This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters, the Company and the
controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal representatives, heirs
and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect
of or by virtue of this Agreement or any provisions herein contained. The term &#8220;successors and assigns&#8221; shall not include
a purchaser, in its capacity as such, of securities from any of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.6 <U>Governing Law; Consent
to Jurisdiction; Trial by Jury</U>. This Agreement shall be governed by and construed and enforced in accordance with the laws of the
State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding
or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York Supreme Court,
County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction,
which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent
an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered
or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 9.1 hereof. Such mailing
shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees
that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&#8217;
fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its
behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby
irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising
out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.7 <U>Execution in Counterparts</U>.
This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which
shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective
when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Delivery
of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient delivery thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


</div></center><!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.8 <U>Waiver, etc</U>. The failure
of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or construed to be a waiver
of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the right of any of the parties
hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance or non-fulfillment of
any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by the party or parties against
whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed
or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[Signature Page Follows]</P>


</div></center><!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose,
whereupon this letter shall constitute a binding agreement between us.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">BIOVIE INC.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">By: </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 53%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">Name: </TD>
    <TD STYLE="width: 43%; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">Cuong V. Do</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">Title: </TD>
    <TD STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Confirmed as of the date first written<BR>
above mentioned, on behalf of itself and as<BR>
Representative of the several Underwriters<BR>
named on <U>Schedule 1</U> hereto:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">THINKEQUITY</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">A Division of Fordham Financial Management, Inc.</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">Name: </TD>
    <TD STYLE="width: 43%; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">Priyanka Mahajan</TD>
    <TD STYLE="width: 53%; padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">Title: </TD>
    <TD STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">Managing Director</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature Page]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">BioVie Inc.
&#8211; Underwriting Agreement</FONT></P>


</div></center><!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>SCHEDULE 1</U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Underwriter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Total Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Firm Shares to be Purchased</B></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">ThinkEquity, a division of Fordham Financial Management, Inc.</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,500,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 0.25pt">TOTAL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,500,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
</div></center><!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 2-A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pricing Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Firm Shares: 2,500,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Public Offering Price per Firm Share: $8.00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Underwriting Discount per Firm Share: $0.32</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Proceeds to Company per Firm Share
(before expenses): $7.68</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 2-B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Issuer General Use Free Writing Prospectuses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Free Writing Prospectus, dated August
6, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


</div></center><!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>SCHEDULE 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>List of Lock-Up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Cuong V. Do</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Jonathan Adams</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Joanne Wendy Kim</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Penelope Markham, PhD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Terren Peizer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Richard J. Berman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Robert Hariri, MD, PhD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">James Lang</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Sigmund Rogich</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Michael Sherman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">&nbsp;</P>


</div></center><!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 381pt">August __, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ThinkEquity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A Division of Fordham Financial Management, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">17 State Street, 22<FONT STYLE="font-size: 12.5pt"><SUP>nd</SUP></FONT>
Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, NY 10004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As Representative of the several Underwriters named on Schedule 1 to the
Underwriting Agreement referenced below</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned understands that
ThinkEquity, a Division of Fordham Financial Management, Inc. (the &#8220;<B>Representative</B>&#8221;), proposes to enter into an Underwriting
Agreement (the &#8220;<B>Underwriting Agreement</B>&#8221;) with BioVie Inc., a Nevada corporation (the &#8220;<B>Company</B>&#8221;),
providing for the public offering (the &#8220;<B>Public Offering</B>&#8221;) of shares of Class A common stock, par value $0.0001 per
share, of the Company (the &#8220;<B>Common Shares</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">To induce the Representative
to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent
of the Representative, the undersigned will not, during the period commencing on the date hereof and ending six months after the date
of the Underwriting Agreement relating to the Public Offering (the &#8220;<B>Lock-Up Period</B>&#8221;), (1) offer, pledge, sell, contract
to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Shares or any securities convertible into
or exercisable or exchangeable for Common Shares, whether now owned or hereafter acquired by the undersigned or with respect to which
the undersigned has or hereafter acquires the power of disposition (collectively, the &#8220;<B>Lock-Up Securities</B>&#8221;); (2) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the
Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities,
in cash or otherwise; (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities; or (4)
publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other
arrangement relating to any Lock-Up Securities. Notwithstanding the foregoing, and subject to the conditions below, the undersigned may
transfer Lock-Up Securities without the prior written consent of the Representative in connection with (a) transactions relating to Lock-Up
Securities acquired in open market transactions after the completion of the Public Offering; <U>provided</U> that no filing under Section
13 or Section 16(a) of the Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;), or other public announcement
shall be required or shall be voluntarily made in connection with subsequent sales of Lock-Up Securities acquired in such open market
transactions; (b) transfers of Lock-Up Securities as a <I>bona fide</I> gift, by will or intestacy or to a family member or trust for
the benefit of the undersigned or a family member (for purposes of this lock-up agreement, &#8220;family member&#8221; means any relationship
by blood, marriage or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution;
(d) if the undersigned is a corporation, partnership, limited liability company or other business entity, (i) any transfers of Lock-Up
Securities to another corporation, partnership or other business entity that controls, is controlled by or is under common control with
the undersigned or (ii) distributions of Lock-Up Securities to members, partners, stockholders, subsidiaries or affiliates (as defined
in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned; (e) if the undersigned is a trust, to a trustee
or beneficiary of the trust; <U>provided</U> that in the case of any transfer pursuant to the foregoing clauses (b), (c) (d) or (e), (i)
any such transfer shall not involve a disposition for value, (ii) each transferee shall sign and deliver to the Representative a lock-up
agreement substantially in the form of this lock-up agreement and (iii) no filing under Section 13 or Section 16(a) of the Exchange Act
or other public announcement shall be required or shall be voluntarily made; (f) the receipt by the undersigned from the Company of Common
Shares upon the vesting of restricted stock awards or stock units or upon the exercise of options to purchase the Company&#8217;s Common
Shares issued under an equity incentive plan of the Company or an employment arrangement described in the Preliminary Prospectus (as defined
in the Underwriting Agreement) (the &#8220;<B>Plan Shares</B>&#8221;) or the transfer of Common Shares or any securities convertible into
Common Shares to the Company upon a vesting event of the Company&#8217;s securities or upon the exercise of options or warrants to purchase
the Company&#8217;s securities, in each case on a &#8220;cashless&#8221; or &#8220;net exercise&#8221; basis or to cover tax obligations
of the undersigned in connection with such vesting or exercise, but only to the extent such right expires during the Lock-up Period, <U>provided</U>
that no filing under Section 13 or Section 16(a) of</P>


</div></center><!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">the Exchange Act or other public announcement
shall be required or shall be voluntarily made within 180 days after the date of the Underwriting Agreement, and after such 180<FONT STYLE="font-size: 12.5pt"><SUP>th</SUP></FONT>
day, if the undersigned is required to file a report under Section 13 or Section 16(a) of the Exchange Act reporting a reduction in beneficial
ownership of Common Shares during the Lock-Up Period, the undersigned shall include a statement in such schedule or report to the effect
that the purpose of such transfer was to cover tax withholding obligations of the undersigned or pursuant to a &#8220;cashless&#8221;
or &#8220;net exercise&#8221; by the undersigned in connection with such vesting or exercise and, <U>provided further</U>, that the Plan
Shares shall be subject to the terms of this lock-up agreement; (g) the transfer of Lock-Up Securities pursuant to agreements described
in the Preliminary Prospectus under which the Company has the option to repurchase such securities or a right of first refusal with respect
to the transfer of such securities, <U>provided</U> that if the undersigned is required to file a report under Section 13 or Section 16(a)
of the Exchange Act reporting a reduction in beneficial ownership of Common Shares during the Lock-Up Period, the undersigned shall include
a statement in such schedule or report describing the purpose of the transaction; (h) the establishment of a trading plan pursuant to
Rule 10b5-1 under the Exchange Act for the transfer of Lock-Up Securities, <U>provided</U> that (i) such plan does not provide for the
transfer of Lock-Up Securities during the Lock-Up Period and (ii) to the extent a public announcement or filing under the Exchange Act,
if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding the establishment of such plan,
such public announcement or filing shall include a statement to the effect that no transfer of Lock-Up Securities may be made under such
plan during the Lock-Up Period; (i) the transfer of Lock-Up Securities that occurs by operation of law, such as pursuant to a qualified
domestic order or in connection with a divorce settlement, <U>provided</U> that the transferee agrees to sign and deliver a lock-up agreement
substantially in the form of this lock-up agreement for the balance of the Lock-Up Period, and <U>provided further</U>, that any filing
under Section 13 or Section 16(a) of the Exchange Act that is required to be made during the Lock-Up Period as a result of such transfer
shall include a statement that such transfer has occurred by operation of law; and (j) the transfer of Lock-Up Securities pursuant to
a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Common Shares involving
a change of control (as defined below) of the Company after the closing of the Public Offering and approved by the Company&#8217;s board
of directors; <U>provided</U> that in the event that the tender offer, merger, consolidation or other such transaction is not completed,
the Lock-Up Securities owned by the undersigned shall remain subject to the restrictions contained in this lock-up agreement. For purposes
of clause (l) above, &#8220;change of control&#8221; shall mean the consummation of any bona fide third party tender offer, merger, amalgamation,
consolidation or other similar transaction the result of which is that any &#8220;person&#8221; (as defined in Section 13(d)(3) of the
Exchange Act), or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of a majority
of total voting power of the voting stock of the Company. The undersigned also agrees and consents to the entry of stop transfer instructions
with the Company&#8217;s transfer agent and registrar against the transfer of the undersigned&#8217;s Lock-Up Securities except in compliance
with this lock-up agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">If (i) during the last
17 days of the Lock-Up Period, the Company issues an earnings release or material news or a material event relating to the Company occurs,
or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results or becomes aware that
material news or a material event will occur during the 16-day period beginning on the last day of the Lock-Up Period, the restrictions
imposed by this lock-up agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings
release or the occurrence of such material news or material event, as applicable, unless the Representative waives, in writing, such extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned agrees that, prior
to engaging in any transaction or taking any other action that is subject to the terms of this lock-up agreement during the period from
the date hereof to and including the 34<FONT STYLE="font-size: 12.5pt"><SUP>th</SUP></FONT> day following the expiration of the initial
Lock-Up Period, the undersigned will give notice thereof to the Company and will not consummate any such transaction or take any such
action unless it has received written confirmation from the Company that the Lock-Up Period (as may have been extended pursuant to the
previous paragraph) has expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned understands that
the Company and the Representative are relying upon this lock-up agreement in proceeding toward consummation of the Public Offering. The
undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned&#8217;s heirs, legal
representatives, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


</div></center><!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><Center><DIV STYLE="width:8in" align="left">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned understands that,
if the Underwriting Agreement is not executed by August 31, 2021 or if the Underwriting Agreement (other than the provisions thereof which
survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Shares to be sold thereunder, then
this lock-up agreement shall be void and of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Whether or not the Public Offering
actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to an Underwriting
Agreement, the terms of which are subject to negotiation between the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 50%; padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">(Name - Please Print)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">(Signature)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">(Name of Signatory, in the case of entities - Please Print)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font: 10pt Times New Roman, Times, Serif">(Title of Signatory, in the case of entities - Please Print)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 5%; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -10pt">Address:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-bottom: 0.5pt; padding-left: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-bottom: 0.5pt; padding-left: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-bottom: 0.5pt; padding-left: 10pt">&nbsp;</TD></TR>
  </TABLE>


  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


</div></center><!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>bivi-20210811_8kex5z1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 2pt 0 0; text-align: center">50 West Liberty Street, Suite 1000, Reno, Nevada
    89501-1950</P>
    <P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center">Telephone: 775-323-1980 Fax: 775-323-2339</P></TD>
    <TD STYLE="width: 54%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 2pt 0 0; text-align: center">3960 Howard Hughes Parkway, Suite 500, Las Vegas,
    Nevada 89169</P>
    <P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center">Telephone: 702-387-6073 Fax: 702-990-3564</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 12pt Times New Roman, Times, Serif; padding-top: 2pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt"><U>www.shermanhoward.com</U></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><B>Exhibit 5.1 </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">August 9, 2021</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps 12pt/97% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-variant: normal">BioVie Inc.</FONT></P>

<P STYLE="font: small-caps 12pt/97% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-variant: normal">2120 Colorado Avenue,
#230</FONT></P>

<P STYLE="font: small-caps 12pt/97% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-variant: normal">Santa Monica, California
90404</FONT></P>

<P STYLE="font: small-caps 12pt/97% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-variant: normal"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps 12pt/97% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-variant: normal"><B><I>Re:</I></B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><I>BioVie Inc.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: small-caps 12pt/97% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps 12pt/97% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-variant: normal">Ladies and Gentlemen:</FONT></P>

<P STYLE="font: small-caps 12pt/97% Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We have acted as
special Nevada counsel to BioVie Inc., a Nevada corporation (the &#8220;Company&#8221;), in connection with an Underwriting
Agreement dated August 8, 2021 (the &#8220;Underwriting Agreement&#8221;) by and between the Company and ThinkEquity, a division of
Fordham Financial Management, Inc., acting as the representative of the underwriters identified therein (the
&#8220;Underwriters&#8221;), related to the offering (the &#8220;Offering&#8221;) of 2,500,000 shares (the &#8220;Firm
Shares&#8221;) of the Company&#8217;s Class A common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) and up to
375,000 Shares of Common Stock (together with the Firm Shares, the &#8220;Shares&#8221;), for which the Underwriters have been
granted an option by the Company.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The Shares are being registered
under a Registration Statement on Form S-3 (File No. 333-252386) (the &#8220;Registration Statement&#8221;) filed with the Securities
and Exchange Commission (the &#8220;Commission&#8221;) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
including the base prospectus forming a part of such Registration Statement dated February 2, 2021 (the &#8220;Base Prospectus&#8221;),
and the prospectus supplement thereto dated August 8, 2021 (the &#8220;Prospectus Supplement&#8221; and together with the Base Prospectus,
the &#8220;Prospectus&#8221;).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">For purposes of these opinions,
we have examined originals or copies, certified or otherwise identified to our satisfaction, of:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Registration Statement;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Prospectus;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
</div></center>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> the Underwriting Agreement; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>resolutions of the Board of Directors and such other matters as relevant related to the (i) approval of the Underwriting Agreement
and authorization of the Company to execute, deliver, and perform its obligations under the Underwriting Agreement, (ii) issuance and
the registration of the Shares under the Securities Act, and (iii) such other matters as relevant.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have also examined such other
corporate charter documents, records, certificates, and instruments as we deem necessary or advisable to render the opinions set forth
herein.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In our examination, we have assumed:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the legal capacity of all natural persons executing the documents;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> the genuineness of all signatures on the documents;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the authenticity of all documents submitted to us as originals, and the conformity to original documents of all documents submitted
to us as copies;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>that the parties to such documents, other than the Company, had the power, corporate or other, to enter into and perform all obligations
thereunder;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>that the Underwriting Agreement is enforceable in accordance with its terms; and</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>other than with respect to the Company, the due authorization by all requisite action, corporate or other, the execution and delivery
by all parties of the documents, and the validity and binding effect thereof on such parties.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The opinions set forth below are
also subject to the further qualification that the enforcement of any agreements or instruments referenced herein and to which the Company
is a party may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, or other similar laws affecting creditors&#8217;
rights generally and by general principles of equity (regardless of whether enforceability is considered in a proceeding in equity or
at law).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As to certain factual matters,
unless otherwise indicated, we have relied, to the extent we have deemed proper, only on certificates of public officials and the factual
representations set forth in the Underwriting Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">On the basis of the foregoing
and in reliance thereon, and subject to the assumptions, limitations, and qualifications set forth herein, we are of the opinion that
the Shares have been duly authorized, and when issued against payment therefor as set forth in the Underwriting Agreement will be validly
issued, fully paid, and non-assessable.&nbsp;</P>

</div></center>
<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The opinions expressed herein
are limited to the matters specifically set forth herein and no other opinion shall be inferred beyond the matters expressly stated. We
disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed herein or any changes in applicable law
that may come to our attention subsequent to the date hereof.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">While certain members of this
firm are admitted to practice in certain jurisdictions other than Nevada, in rendering the foregoing opinions we have not examined the
laws of any jurisdiction other than Nevada. Accordingly, the opinions we express herein are limited to matters involving the laws of the
State of Nevada (excluding securities laws). We express no opinion regarding the effect of the laws of any other jurisdiction or state,
including any federal securities laws related to the issuance and sale of the Shares.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><BR>
&#9;We hereby consent to the use of this opinion letter as Exhibit 5.1 to the Registration Statement and to the use of our name under
the caption &#8220;Legal Matters&#8221; in the Prospectus Supplement. In giving the foregoing consent, we do not hereby admit that we
are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission
thereunder.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-align: left">Very truly yours,</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-align: left">/s/ Sherman &amp; Howard L.L.C.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-align: left">SHERMAN &amp; HOWARD L.L.C.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
</div></center>
<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>bivi-20210811_8kex99z1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="image_002.jpg" ALT=""></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">BioVie Inc. Announces Pricing
of Public Offering of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>SANTA MONICA, Calif., August 8,
2021 </B>(GLOBE NEWSWIRE) &ndash; BioVie Inc., (NASDAQ: BIVI) (&ldquo;BioVie&rdquo; or the &ldquo;Company&rdquo;) a clinical-stage
company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain
cancers, today announced the pricing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering
price of $8.00 per share, for gross proceeds of $20,000,000, before deducting underwriting discounts, commissions and offering expenses.
In addition, the Company has granted the underwriters a 45 day option to purchase up to an additional 375,000 shares of common stock to
cover over-allotments at the offering price, less the underwriting discount.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">ThinkEquity, a division of Fordham
Financial Management, Inc., is acting as the sole book-running manager for the offering. EF Hutton, division of Benchmark Investments,
LLC, is acting as a financial advisor for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The Company intends to use the net proceeds
from the offering primarily for general corporate purposes.</P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The securities will be offered and
sold pursuant to a shelf registration statement on Form S-3 (File No. 333-252386), including a base prospectus, filed with the U.S. Securities
and Exchange Commission (the &ldquo;SEC&rdquo;) on January 22, 2021 and declared effective on February 2, 2021. The offering will be made
only by means of a written prospectus and prospectus supplement that forms a part of the registration statement. A prospectus supplement
and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov. Copies of the
prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available from the offices of ThinkEquity,
a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673
or by email at prospectus@think-equity.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">This press release shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state
or jurisdiction.</P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0.35pt 0 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">About BioVie</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">BioVie Inc. (NASDAQ: BIVI) is a clinical-stage
company developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the
Company&rsquo;s orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US
Phase 2 study for the treatment of refractory ascites with top-line results expected in early 2022. The Company is also planning a pivotal
Phase 3 study of BIV201 in the treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI) in 2022. BIV201 is administered as a patent-pending
liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not
available in the US or Japan. In neuro-degenerative disease, BioVie recently acquired the assets of NeurMedix Inc., including NE3107 that
inhibits inflammatory activation of ERK and NFB (e.g. TNF transcription) that leads to neuroinflammation and insulin resistance, but not
their homeostatic functions (e.g. insulin signaling and neuron growth and survival). Both are drivers of Alzheimer&rsquo;s and Parkinson&rsquo;s
diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter
study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028). An estimated six million Americans suffer
from Alzheimer&rsquo;s. BioVie has initiated this study and is targeting primary completion in late 2022. A Phase 2 study of NE3107 in
Parkinson&rsquo;s disease is planned for later this year, and related compounds have additional potential to treat certain cancers. NE3107
is patented in the United States, Australia, Canada, Europe and South Korea. For more information, visit http://www.biovieinc.com/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

</div></center>
<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.25pt 0 0 0">Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.6pt 0 0; text-align: justify"><I>This press release contains forward-looking
statements, which may be identified by words such as &quot;expect,&quot; &quot;look forward to,&quot; &quot;anticipate&quot; &quot;intend,&quot;
&quot;plan,&quot; &quot;believe,&quot; &quot;seek,&quot; &quot;estimate,&quot; &quot;will,&quot; &quot;project&quot; or words of similar
meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that
its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to
the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and
statutory limitations that could impair our ability to pay future dividends, our ability to complete our clinical studies and to obtain
approval for our product candidates, to successfully defend potential future litigation, changes in local or national economic conditions
as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed
from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual
reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking
statements), except as required by law.</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.5pt 0 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0"><B><I>For Investor Relations Inquiries:</I></B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 376.95pt 0 0"><B>Bruce Mackle</B><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 376.95pt 0 0"><I>Managing Director</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 376.95pt 0 0"><I></I><B>LifeSci
Advisors, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0 0; color: #00467F">bmackle@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
</div></center>
<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>bivi-20210811_8kex99z2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>

<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 86px; width: 216px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc. Announces Closing of Public Offering
of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>SANTA MONICA, Calif., August 11, 2021</B> (GLOBE
NEWSWIRE) &#8211; BioVie Inc., (NASDAQ: BIVI) (&#8220;BioVie&#8221; or the &#8220;Company&#8221;) a clinical-stage company developing
innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today
announced the closing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering price of&nbsp;$8.00&nbsp;per
share, for gross proceeds of &nbsp;$20,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition,
the Company has granted the underwriters a 45 day option to purchase up to an additional 375,000 shares of common stock to cover over-allotments
at the offering price, less the underwriting discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ThinkEquity, a division of Fordham Financial Management,
Inc., acted as the sole book-running manager for the offering. EF Hutton, division of Benchmark Investments, LLC, acted as a financial
advisor for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company intends to use the net proceeds from the
offering primarily for general corporate purposes.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities were offered and sold pursuant to a
shelf registration statement on Form S-3 (File No. 333-252386), including a base prospectus, filed with the U.S. Securities and Exchange
Commission (the &#8220;SEC&#8221;) on January 22, 2021 and declared effective on February 2, 2021. The offering was made only by means
of a written prospectus and prospectus supplement that forms a part of the registration statement. A final prospectus supplement and accompanying
prospectus describing the terms of the offering has been filed with the SEC on its website at www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to the offering may be obtained from the offices of ThinkEquity, a division of Fordham
Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673 or by email at prospectus@think-equity.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state
or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>About BioVie </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company
developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the Company&#8217;s
orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2 study
for the treatment of refractory ascites with top-line results expected in early 2022. The Company is also planning a pivotal Phase 3 study
of BIV201 in the treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI) in 2022. BIV201 is administered as a patent-pending liquid
formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available
in the US or Japan. In neuro-degenerative disease, BioVie recently acquired the assets of NeurMedix Inc., including NE3107 that inhibits
inflammatory activation of ERK and NFB (e.g. TNF transcription) that leads to neuroinflammation and insulin resistance, but not their
homeostatic functions (e.g. insulin signaling and neuron growth and survival). Both are drivers of Alzheimer&#8217;s and Parkinson&#8217;s
diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter
study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028). An estimated six million Americans suffer
from Alzheimer&#8217;s. BioVie has initiated this study and is targeting primary completion in late 2022. A Phase 2 study of NE3107 in
Parkinson&#8217;s disease is planned for later this year, and related compounds have additional potential to treat certain cancers. NE3107
is patented in the United States, Australia, Canada, Europe and South Korea. For more information, visit&nbsp;http://www.biovieinc.com/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
</div></center>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><I>This press release contains forward-looking
statements, which may be identified by words such as &quot;expect,&quot; &quot;look forward to,&quot; &quot;anticipate&quot; &quot;intend,&quot;
&quot;plan,&quot; &quot;believe,&quot; &quot;seek,&quot; &quot;estimate,&quot; &quot;will,&quot; &quot;project&quot; or words of similar
meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that
its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to
the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and
statutory limitations that could impair our ability to pay future dividends, our ability to&nbsp;complete our clinical studies and to
obtain approval for our product&nbsp;candidates, to successfully defend potential future litigation, changes in local or national economic
conditions</I>&nbsp;<I>as well as various additional risks, many of which are now unknown and generally out of the Company's control,
and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports
on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including
any forward-looking statements), except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>For Investor Relations
Inquiries:</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 67%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Contact:<BR>
<B>Bruce Mackle</B><BR>
<I>Managing Director</I><BR>
<B>LifeSci Advisors, LLC</B><BR>
<FONT STYLE="color: #00467F">bmackle@lifesciadvisors.com</FONT></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
  </div></center>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>
<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !L 0X# 2(  A$! Q$!_\0
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G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !O GT# 2(  A$! Q$!_\0
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ME?\ Z JGW!R+N?1]%?.'_"!?&7_H,W/_ (-:/^$"^,O_ $&;G_P:T?VY7_Z
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ME?\ Z JGW!R+N?1]%?.'_"!?&7_H,W/_ (-:/^$"^,O_ $&;G_P:T?VY7_Z
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ME?\ Z JGW!R+N?1]%?.'_"!?&7_H,W/_ (-:/^$"^,O_ $&;G_P:T?VY7_Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZFT_3[72;"VL;*VBL[*VC6&"W@0)'%&H 554<     =,5\-?\%>?^2&^$/\
ML8/_ &TGK+!QA4Q<5R^ZWL]1O8^QOA?K5YXE^&?A'5]1E$VH:AH]G=W,BJ%#
MRR0HSG X&23P*Z>N*^"/_)%_ '_8OZ?_ .DT==K7#/232&?)O_!1?X]>-_V?
M_ACX:UCP-JL6DZA>ZLUK/)+:1W :,6\KXQ("!\R@Y'I7T=\,]8N_$7PW\*:M
MJ$@FO[_2;2ZN) H4-(\*,QP.!DD\"OC'_@KY_P D5\&?]AYO_22:OL'X,_\
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MC3X)_:BTGX<?#/6+> :K86?V2PELK:0R7,KRK_K)5XSL7J<#%9_VW_@H"/\
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MM7$9*E<_QAMNW'.[&.:]*&.=:2CB(*5_*S^]$V[%_P"#GQ@\-_'3X?Z=XO\
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M\?C9+^T_\3/"_P #?AA(NN)#J(:\N[8[H)KW!4 ,.#' AD=WZ9_W:_0_X8>
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M^%?_  N+]G'QGH,,0EU**T.HV QD_:(/WJ >[;2G_ S5O$QCCDU\*]WY;?\
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ME))16UMK=_F-'YK_ +37_*4;X4_[VC_^CIZ_2BOS7_::_P"4HWPI_P![1_\
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M=C;V=I"EO:6\:PPPQC"HB@!5 [   5/145*TJD(TWM'8 JMJ6G6VL:==6%[
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MW^Q_\6OBM^T9I_Q&^'M_I&F'3["UCM;JZO6BN(;B)Y6WJOEL.-XP3[\5S1^
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M-']J8#_G_#_P)?YARR['?T5P'_"^? O_ $'%_P# >7_XFC_A?/@7_H.+_P"
M\O\ \31_:F _Y_P_\"7^8<LNQW]%<!_POGP+_P!!Q?\ P'E_^)H_X7SX%_Z#
MB_\ @/+_ /$T?VI@/^?\/_ E_F'++L=_17 ?\+Y\"_\ 0<7_ ,!Y?_B:/^%\
M^!?^@XO_ (#R_P#Q-']J8#_G_#_P)?YARR['?T5P'_"^? O_ $'%_P# >7_X
MFC_A?/@7_H.+_P" \O\ \31_:F _Y_P_\"7^8<LNQW]%<!_POGP+_P!!Q?\
MP'E_^)H_X7SX%_Z#B_\ @/+_ /$T?VI@/^?\/_ E_F'++L=_17 ?\+Y\"_\
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M\PY9=COZ*X#_ (7SX%_Z#B_^ \O_ ,31_P +Y\"_]!Q?_ >7_P")H_M3 ?\
M/^'_ ($O\PY9=COZ*X#_ (7SX%_Z#B_^ \O_ ,31_P +Y\"_]!Q?_ >7_P")
MH_M3 ?\ /^'_ ($O\PY9=COZ*X#_ (7SX%_Z#B_^ \O_ ,31_P +Y\"_]!Q?
M_ >7_P")H_M3 ?\ /^'_ ($O\PY9=COZ*X#_ (7SX%_Z#B_^ \O_ ,31_P +
MY\"_]!Q?_ >7_P")H_M3 ?\ /^'_ ($O\PY9=COZ*X#_ (7SX%_Z#B_^ \O_
M ,31_P +Y\"_]!Q?_ >7_P")H_M3 ?\ /^'_ ($O\PY9=COZ*X#_ (7SX%_Z
M#B_^ \O_ ,31_P +Y\"_]!Q?_ >7_P")H_M3 ?\ /^'_ ($O\PY9=COZ*X#_
M (7SX%_Z#B_^ \O_ ,31_P +Y\"_]!Q?_ >7_P")H_M3 ?\ /^'_ ($O\PY9
M=COZ*X#_ (7SX%_Z#B_^ \O_ ,31_P +Y\"_]!Q?_ >7_P")H_M3 ?\ /^'_
M ($O\PY9=COZ*X#_ (7SX%_Z#B_^ \O_ ,31_P +Y\"_]!Q?_ >7_P")H_M3
M ?\ /^'_ ($O\PY9=COZ*X#_ (7SX%_Z#B_^ \O_ ,36SX7^)'ASQI>36FC:
MB+RXAC\UT$3KA<@9^8#N16E/,,'5DH4ZT6WT4DW^8<LNQTU%%%=Y(5C>+?"=
MAXUT.72=2$IM)65V\E]C94@CGZBMFBLZE.%6#IU%=/1H#RO_ (9K\&_W=0_\
M"C_A1_PS7X-_NZA_X%'_  KU2BO)_L7+?^?$?N1?/+N>5_\ #-?@W^[J'_@4
M?\*/^&:_!O\ =U#_ ,"C_A7JE%']BY;_ ,^(_<@YY=SRO_AFOP;_ '=0_P#
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M^!1_PKU2BC^Q<M_Y\1^Y!SR[GE?_  S7X-_NZA_X%'_"C_AFOP;_ '=0_P#
MH_X5ZI11_8N6_P#/B/W(.>7<\K_X9K\&_P!W4/\ P*/^%'_#-?@W^[J'_@4?
M\*]4HH_L7+?^?$?N0<\NYY7_ ,,U^#?[NH?^!1_PH_X9K\&_W=0_\"C_ (5Z
MI11_8N6_\^(_<@YY=SRO_AFOP;_=U#_P*/\ A1_PS7X-_NZA_P"!1_PKU2BC
M^Q<M_P"?$?N0<\NYY7_PS7X-_NZA_P"!1_PH_P"&:_!O]W4/_ H_X5ZI11_8
MN6_\^(_<@YY=SRO_ (9K\&_W=0_\"C_A1_PS7X-_NZA_X%'_  KU2BC^Q<M_
MY\1^Y!SR[GE?_#-?@W^[J'_@4?\ "C_AFOP;_=U#_P "C_A7JE%']BY;_P ^
M(_<@YY=SRO\ X9K\&_W=0_\  H_X4?\ #-?@W^[J'_@4?\*]4HH_L7+?^?$?
MN0<\NYY7_P ,U^#?[NH?^!1_PH_X9K\&_P!W4/\ P*/^%>J44?V+EO\ SXC]
MR#GEW/*_^&:_!O\ =U#_ ,"C_A1_PS7X-_NZA_X%'_"O5**/[%RW_GQ'[D'/
M+N>5_P##-?@W^[J'_@4?\*/^&:_!O]W4/_ H_P"%>J44?V+EO_/B/W(.>7<\
MK_X9K\&_W=0_\"C_ (4?\,U^#?[NH?\ @4?\*]4HH_L7+?\ GQ'[D'/+N>5_
M\,U^#?[NH?\ @4?\*/\ AFOP;_=U#_P*/^%>J44?V+EO_/B/W(.>7<\K_P"&
M:_!O]W4/_ H_X4?\,U^#?[NH?^!1_P *]4HH_L7+?^?$?N0<\NYY7_PS7X-_
MNZA_X%'_  H_X9K\&_W=0_\  H_X5ZI11_8N6_\ /B/W(.>7<\K_ .&:_!O]
MW4/_  */^%'_  S7X-_NZA_X%'_"O5**/[%RW_GQ'[D'/+N>5_\ #-?@W^[J
M'_@4?\*/^&:_!O\ =U#_ ,"C_A7JE%']BY;_ ,^(_<@YY=SRO_AFOP;_ '=0
M_P# H_X4?\,U^#?[NH?^!1_PKU2BC^Q<M_Y\1^Y!SR[GE?\ PS7X-_NZA_X%
M'_"C_AFOP;_=U#_P*/\ A7JE%']BY;_SXC]R#GEW/*_^&:_!O]W4/_ H_P"%
M'_#-?@W^[J'_ (%'_"O5**/[%RW_ )\1^Y!SR[GE?_#-?@W^[J'_ (%'_"C_
M (9K\&_W=0_\"C_A7JE%']BY;_SXC]R#GEW/*_\ AFOP;_=U#_P*/^%'_#-?
M@W^[J'_@4?\ "O5**/[%RW_GQ'[D'/+N>5_\,U^#?[NH?^!1_P */^&:_!O]
MW4/_  */^%>J44?V+EO_ #XC]R#GEW/*_P#AFOP;_=U#_P "C_A1_P ,U^#?
M[NH?^!1_PKU2BC^Q<M_Y\1^Y!SR[GE?_  S7X-_NZA_X%'_"C_AFOP;_ '=0
M_P# H_X5ZI11_8N6_P#/B/W(.>7<\K_X9K\&_P!W4/\ P*/^%'_#-?@W^[J'
M_@4?\*]4HH_L7+?^?$?N0<\NYY7_ ,,U^#?[NH?^!1_PH_X9K\&_W=0_\"C_
M (5ZI11_8N6_\^(_<@YY=SRO_AFOP;_=U#_P*/\ A1_PS7X-_NZA_P"!1_PK
MU2BC^Q<M_P"?$?N0<\NYY7_PS7X-_NZA_P"!1_PKH?!/PFT'X?ZE<7VDBZ$\
GT7DOY\Q<;<@\#'7(KLZ*UI95@:$U4I48J2V:0<TGHV%%%%>J0?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bivi-20210808.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6Ips7xRiXgen8uHZH0sSaeHSbPtzpN2iekhtWpzfenqzyArbeeAVCr5MXpW4SsE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:bivi="http://nanoantibiotics.com/20210808" elementFormDefault="qualified" targetNamespace="http://nanoantibiotics.com/20210808">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://nanoantibiotics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20210808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20210808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>bivi-20210808_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>bivi-20210808_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Cover" xlink:href="bivi-20210808.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>bivi-20210811_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bivi-20210808.xsd" xlink:type="simple"/>
    <context id="From2021-08-08to2021-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <startDate>2021-08-08</startDate>
            <endDate>2021-08-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-08-08to2021-08-08">0001580149</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-08-08to2021-08-08">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-08-08to2021-08-08">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-08-08to2021-08-08">2021-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-08-08to2021-08-08">BioVie Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-08-08to2021-08-08">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-08-08to2021-08-08">000-55292</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-08-08to2021-08-08">46-2510769</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-08-08to2021-08-08">2120 Colorado Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-08-08to2021-08-08">#230</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-08-08to2021-08-08">Santa Monica</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-08-08to2021-08-08">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-08-08to2021-08-08">90404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-08-08to2021-08-08">(310)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-08-08to2021-08-08">444-4300</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-08-08to2021-08-08">Class A Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-08-08to2021-08-08">BIVI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-08-08to2021-08-08">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="From2021-08-08to2021-08-08">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-08-08to2021-08-08">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-08-08to2021-08-08">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-08-08to2021-08-08">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-08-08to2021-08-08">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140188016180920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-55292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioVie Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001580149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-2510769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2120 Colorado Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Santa Monica<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">444-4300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIVI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG9A1<^(V$,>?KY]"0U_N9I+8$B8A-X09AR0M<Y<<%VANIIT^"%N )K9$93G
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MN_3(B/,(TB/@#=ON"&%3!MO-;[-9??T:]!K)*N-GN$O_AVR893F0-0+BLHV
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #C:@M3JL0B%C,!   B @  #P
M 'AL+W=O<FMB;V]K+GAM;(U1T6[", S\E2H?L!:T(0U17D#;D*8-C8GWT+K4
M(HDKQX6-KY_;JAK27O:4W-FZW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX1PT$
MG53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7<P
M.6/$ SJ4[]ST=P<F\1C0XQ7*W&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7
MF?RTA]@S8@\?5HWD9I:I8(4<I=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.G8RF
M2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMR
MR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7
MLN48<?R>Y0]02P,$%     @ XVH+4R0>FZ*M    ^ $  !H   !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C
M$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C
M,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI
M160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%
MKLWC":[?#'!X=/X!4$L#!!0    ( .-J"U-ED'F2&0$  ,\#   3    6T-O
M;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^
MDV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT
M(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"
MS&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE
M8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F
M"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECF
MS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ XVH+4P=!
M36*!    L0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4    " #C:@M3EA^*'^X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #C:@M3F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( .-J"U/@DNTC- 0  +40   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #C:@M3GZ ;\+$"  #B#
M#0              @ %W#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .-J
M"U.7BKL<P    !,"   +              "  5,/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( .-J"U.JQ"(6,P$  "("   /              "  3P0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #C:@M3)!Z;HJT   #X 0  &@
M            @ &<$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #C:@M399!YDAD!  #/ P  $P              @ &!$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #+$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="bivi-20210811_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="bivi-20210811_8k.htm">bivi-20210811_8k.htm</File>
    <File>bivi-20210808.xsd</File>
    <File>bivi-20210808_lab.xml</File>
    <File>bivi-20210808_pre.xml</File>
    <File>bivi-20210811_8kex1z1.htm</File>
    <File>bivi-20210811_8kex5z1.htm</File>
    <File>bivi-20210811_8kex99z1.htm</File>
    <File>bivi-20210811_8kex99z2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bivi-20210811_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "bivi-20210811_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bivi-20210808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bivi-20210808_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bivi-20210808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "bivi",
   "nsuri": "http://nanoantibiotics.com/20210808",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210811_8k.htm",
      "contextRef": "From2021-08-08to2021-08-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://nanoantibiotics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "bivi-20210811_8k.htm",
      "contextRef": "From2021-08-08to2021-08-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://nanoantibiotics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001520138-21-000423-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001520138-21-000423-xbrl.zip
M4$L#!!0    ( .-J"U-1BMR5,@,   $,   1    8FEV:2TR,#(Q,#@P."YX
M<V2U5DUSVC 0/;<S_0^J[[(-:=) ()E,TC3,D#03FH_II2/;"VAB)$>2@>37
M5Y)M(&!<(*U/\NY[;W>E7=FMD^DH1F,0DG+6=FJN[R!@(8\H&[2=NQX^[9UU
M.@XZ.?[T$>FG]1EC=$$ACIKHG(>XP_K\"%V3$331=V @B.+B"-V3.#46?D%C
M$.B,CY(8%&A'%JF)]MT&01AO('L/+.+B[K8SDQTJE<BFYTTF$Y?Q,9EP\23=
MD(\V$^PIHE(Y4_.G?OYL1K^B,IR1O8-.(K].;^GC -AA>OGKTI<] I>]X$:]
M)M=U"D]#]9"\]H$]O[Z<B@#@]/Y,[%\])@]?>O);%K(EPR&,"-)GP63;,?7E
MY4WV7"X&7MWW:][C5;=G<4X&;$YCRI[*X+5&H^%9;P%=04X#$1?2>YYQ!T3"
M3%E[:06>,JD("]_@(S4C+(+WO<SY!DI+H0<9E!;0")9P$D)WP,>>=FA\O58
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M3O4RU*P K>0S8E45Z'=9"2IJL?U^>7/3M?@D-JM-XJ\5SHC8\E]02P,$%
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MA4B\'Q41FCD^$.#'UD#B?Z#>>'@T(B$?SRGG+I\C M3+J^R!V/_$Q.[7^0K
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M*7Q3!"@.C0_J&X7 &"K"=-$YTG5K#[BWU1;?N%_NC:SVR/]02P,$%     @
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M]%WB]FW;D ")Q3""$.3][05!L38W@-#8VD/Y#*P5! X &>-K%,+CJ%$M^T-
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M=][-^[.W"#,,6@^7ORD6=0<.(BA/6+QLVI:+$GV"1JXLT(5LZ@I49P?&3;L
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MY(ECVX>A\<<>^ZS?M:?%?*;AIR;8S:WN9M&!50(24N5TM.$1IG_0\8U0*D*
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MY;ZB^M)IN0S*Q'3BY$^G$/M)#3-GJMQ6Z ))\2?JI4%9H81@O0DRHNPV(9S
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M6E4<"U\U<!317G'4V_&(HWFLF#I#&\C"LTP;15_(X^])C:MNC\#^*/R;[YG
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MTVP)OOZ<81##MK-X\:2 ?3$362WF,\<ZU*[(RD6($B:_,59B\TV;\J(C7]2
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M\P@=)H6ETR%*'J#K4YD4>VVHNX#-*Y#X5/-/A ];TD*GGCPOE;Z"+YT9EV"
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M\"+'2+E*"D.HZQQB^]@]C#<"8F;0_TO% 61>NS59U\F[9'UPQO80*@!LA*R
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M,#H1^V>R))+,Y2=@Q1>M'TSF"#V]%NKU*##,56OC,(W;E<B(^X@:$)-%+A'
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M&#M-?OTG*(.=@Q^>@10\:EOST3?U_>1E;93<ZZHVU__G/,/"DU>HYE$9/J.
M^=K']6/VX7MSX7;-E=L_>+R]=WBX\[4<)8P(00_\;-%E58!B"RJK9- $8(+\
M:F[)N[-\9HQ^<Q3>S,%P2I/?S?1 &/Z_;#I[DOQL_KLUTMA8'&M_]_Z.^?#P
M?3XVJMN\\.TD^W=VT]=A=W=O[:\X@J(;4,;?)[\88[K.%\DO]Y,?C24] :W\
MLOG7^I6)N4W&7S87ZO'NPT%RL/]H^\'N_O[7<NJ<<F$3_:NY+\^*ZA]%;N3E
M</U[:F3CCEF0255GHRHY,L;-/#??,!HL3_;VUR\MWQF7,4O>(--AFCP_2A[O
M'!AM<:V,W\.[C)^?\7MXE_&[AOQ\/J^, _*/^\F+ZN9$YO[NCA&9!P?;!_L[
M=S;(YY_:ZRH_87,#_WDCML;!(3#QO$>QNLAOW,PX/+A),^--T0[/ /3VUWG3
MG&3SZ4U;&6BV'^P\W#YX_/B+OC(KQ-H>4SG=ST2GJBJWS_@WQ&"AN[.Q[<]F
M:ZM)+HB/U/!EG*BR0#%O?K0@K6D0UU=!?4P?8>R=8K"MAM_CJCKC?+><1G*U
M "J47W^"9-(7'\5_3$GC(^GN<S6LNC,.^D<03EOQL&/IER--;MJ:J)PUW;(4
M8D@C-,3U*=1^:Y87LW8OC?@Q%\"N:+Q2>*NM3BF%YBHI6DO5ZKHX74_G28Z@
MGC: I_/C50\EB][9@5* E 5'M($Z=Z^,;U\<%IH9,J=9BRB>E%+F)#1CCB-.
M'L.--<C,136S;HJ4],7 K"0TFV 04/G">7H^@#V ZK$!==*E25])Q.:&0ZJ6
M&H,"$YD\NJH:N325;8$.5DKP?Z3# H4/!UAMF<^8/@;18<@\46,++O\D;Y&H
M2=B#PVIQ%:U+H36^X%POP!(9I^ LFQI[57J=WF0E/S=%3RS% J61<;E/ZCGD
MBG=WTV1O9V\W79)XI0VBY-?GZD)]3,G'9P7M(-7A,\3G<:Q&I2@AJPN:9V)+
M0!BZ7I):CE",GXIE%-U ;I>R+.WL"A91Z*P:=Q]J!B@$W);L7,!($&(W6&AW
M'X2IF2.6-_+T$<^V#RII?@U?X3N5-= ,T*2,A1=P=;E:M@I1B%$RU'.&G4:T
M*@%AQMXK"U>-)?*0R9CFHX4%2$YL^8!#*45%3%72YT7=SF-])9*8=*J9+0AK
M4G3;O-TR)&J>TM&G#0AL[3:K8<$'ZE20S8;9+(.^,>D 3+%@SQ6G63#22 G,
MK=%F#^#6_83%ZW"J7V<73\RYQZ8Y+ 7\Q:M=/Z9ZS 7\>A&S+-R=HX)XP8(8
MJ=.'PH9* JFF?3@T<@UYR5S7;'8A.H*+ON$GYUI()^!I@17VG+@G),GQI"!.
M/7R(T49&5,XFN2TZ\YL2&7M D!+.N/M#D&,U#JB]"8(76[0!>RM6<%H,(F7>
M=J$!NFR'P;+XC1?S&5Q'*!*K@102BL4(M=>M257+U_R6@A<%,S7BEZW1_LX,
M^0P:'NW?O:=AA8018.?5$('8J<:BL2 &NJDA!1K1(OBE L/^8&YI8Z17=.4O
M,I!K=!%1NPO1 M6:\5?]1Y/LE((T:%34%<%(^%N4U@O!.<^G"L@6=[6A4HPY
M0# (R#+TDN<CIRADK$+'2'\&NX 2M"VEB2D8(35W"&4N.6(Z-E=,$J<(<@)1
M*#.5&0*D.& P4"2M\&WSKWWJ#5$RD"^7L_Y.97(5!A4GCB4E34WTP@PH'R+=
M +_J:%#%[!Z_+@Y8/T+?B+!<PI^=G]/HJ(-MJP""%<U-'M*#:O@LLX+(+F)Y
M7U0O'#T)#34I&;?X,,9^K(QT6@@YJ:K3],M!V8H,& ,T$C'50EN>@A[61-Q/
MQE;!<V(VS5^9K0K5%AB&6$N$_"]+X'M=ISTA^7I52##=!OJQ@*!.4)$R6X-$
MY/7:F?.A+!G51M]_NJ9V1& ]FB-[I9%IVE[7?B>JQ%QL>XSHP.G5)?%J+A&Q
M8VOQVI6I+-F6%^Z>W)8FR<?W'U+Y.+COC"[_7+64QJUKEG36Z6?P/6@I ?A!
MW9-*2H*=I%$QQBA/&[I+ /=%9S_\MIP_U!U=V402.2LMWD[*-%X31Y@+S"N@
M+=C-ID>H&# ,78JFJ</6+W&-]_*".LO[Y^W:V)@X>VE@)&CJA7X(]5DGKU0H
M)7G!Y7D4Z)+7J#%$[&RO?@CL>1#ZW\U&8[^8J+-$Y^8L<561H[:T]8%B,WU-
M.+"/[C)P?@;NT5T&;FTR]1'(U#]!&4*983MTP7*N- ^#TV'TJ/(:S*4W2G]A
M21#;+XIG04F,&,ZW!ZE)^KJV@Q&SEYZ<$EIGI5V4W 7>4204P@JRU)NWO7"U
MZJZ/+L#FAEL!E"I4:2@+@$(1K1*4.^X%W4 ^D/K0].1-U"&8(E@AXC8A7STU
M+I3;QE8QAL_$XBFNMM8G&N1A7DXZ5O>E07-9!!\&D7Q(4#45=KN30N/ED$ M
M;AO/U8R-Z."?2+S'7P3\[-57PL[.GAUT57SE&[RBDGX00-!#,=)>_8TWH4-(
MV-Y[^O_?"2H&RKWD1\3::?[G>@KD\9T"\17(XSL%LNQ,KM/"OT;LG$G/895/
M*V*D09K'"24\&A95\!DO"Y/H%$070U<W)L\0*@J*RR$0 !TYEIMUE@US10B<
MFWO',2:CYS@IC $BJ,ZG\(&19)0%Z5JCF0TUN(25#'.NPK+7[0>QUW)H)$0V
M:\RYE']=VBI"1S32+3++1C!DV)"]0WU0O1Z/Y[_!6'_]SWO[]WJ^N$H+R3_0
M.J_GDP6!MZ=!G\=GG(;WQ2]B1*LL[+-7O_WCU<ODU:_/P]:96[2D:UC&Q?=)
MWS3W[#0#'7D2ZL@G23 $]S]K7166$(?[?^N\\4H-8'OK^]XJBTR*>GEK6F1*
MJ[S"JT/\G(?OQD[J,423^U;Q8U;NK,C'"8??SI%?%5+#-]*/M]88XSU@W)1N
M,UNJ@<@GA(?)_@YUTQ!+\)0*\A"$*PA$YQ3,-H^B+X10!/3X&!,"?;[,I@1#
M:QSO=\.S'#A1DUWPN]FG7D]YY]I:3M=K8JQ7N1W__.K7O[_\KS]>'?]S]4MW
MO:N_HG+[(D:TRI(>)2]6*M'Y<F;YJ==]+4;%)[4I/MVB?/-VQ-NZ6&3E^\S<
MA[/LKZQ<^K)+[;"OP@2^*<,")0H"D7+IV<><U9O  Y"H7+<3^#RKBPR>WDR-
MX[\]-$K1C0L[@6\P2'@WG&]O.$'@]W^^F(&I]LC-#:PRV7WBC%NXO:IXW!OS
M2K'J_9V[6+47J][?N8M5+W=SOK"+?M.A<WMOGP$^SKOG/[]\\8?QZ]"!_.&[
M9T\C_I[V[T+_SS<RNR[>DV05]*%>&X5F?U)-1E=:@MB$/7IMT/G7P1EB(\(>
M^=U5@IC7@S,2F;**3%J?='_V]+AJ,^@G9+X:.2/)S;Q-D_91TO6MT.C)FU>T
M>,W*F94ZK:MY.8(#6M7?)_7IR=;>SD&ZM_\HW3L\'/1[( \A@'&]C0,)Y4X,
M_.1LSX_J:@F/K[UA*PQUN95_V5ESM_JC5L>WP:_S^D?7?C^69MQ[NI<>$K!H
MWZ*N<8(?=63_/#.2Z^,E8RC $(2H]Y3^=GST>GW"<N_R@$)TYP_,JT;5_&22
M?[+#]O&OO.Q\]6S$VL_:33JTVE99Q4C?O3/2?2-]]\Y(O\1(?V8']^Q&O5G?
M*M[;/NK8Q5^RR=\_J[=U,00O^Q44U$TSPE9>TZS6G&VSIJ9F1S "TDG2+V_,
M#!#[&Q,#)+#<2,FIYO!]\A^/[G^9P_<",4!NC*#IG>'OW-]?#TC:FH?ON?!=
MT^F"3*>WU$>#?H5T&?E3W-S8(F%JNYX&9M8/[S]X] GB:)]+PCW[!!+N$T[N
M%; WULE/S OR1Y,G/]9YGOS)I]L1= -T[I<I :]VGGNF)9@'1_/3.114/R#$
M@W6>X*N.</TQLX]Z\VI&ZMZ=D>H;J7MW1NHG-E)7BN#N?UMR_'718,O'ZVKX
M?ON/&6"T0:/(UVZ*KQO',/Z67ZHR ZKCY&B439L;?5%6ED8+Y>5HD?R]F-[@
MJ]X:C3ZI9CE2:IYETS1Y>_;B!M]W#'@U9?(V+_X-&8,;>P_ *@/+^R_WDV>Y
M<<W*FWQ793RK-ODYJXNZ2),W+VYZ$7_)X-NOLS7!AL=?\JXXG1H3P'SWU*SE
M#;[H#6Q5/C'.PMHV:KF(_XBVW_W]._O%MU_V[^R7+]!^>?G?/[]Z]NHX^12!
MMD]IOK#9HJI:;N25F&8(^N#V'V%:FAS Y'__5QS M?A?ZV;/N$[%\%I>NT:J
MCJI:CX$0Y>A8TR(W(<'BDD:#Q/88N 8#2YT8+]IRJ+;<]'AS"!DW#R!S[^GK
M;"0<;3^9V4U@CNOIJ_CB<7*.;5\LP:RX'EG"@T.('%V\L-KM3;;@U#&PH1&4
M_JD$*<FXA@.$SX)VV898<Z%!MB@10<:K'/0A9KV']Q48NI<0))6J3DR1\/T\
M&P&*63VK&*0J>##'C[WA;FY0VR^\2U#E9I07$,+@\#%!VL ;&, =4!V,^=?S
M2=8TR1%2? %J#6!9I0"> . 4\QQ"\T98[$(\&Y&#@+R]\EFDNS. )U%V1;_X
M<T&>'F,S]=Q89%U(4L1>!.BJHISGB.:5CZ&+N^G#%PL6-E7=WG2JNSB'#D61
MD#  M5>0+(8" 5G%>+*[3P>:<$ E29/1O!;20;,W137"+31R$C'AR@Z)-L$>
MXAEJB@^)V:+VK D(M^TP>D6QA@3K+$9X$FR$!<?GW\"MW0$=7NQY'YV:N0)9
M8VK)JW%GZ%>GP&P).*V U"8L[$@QAXA+8X+*&!4-XZ(+5NQD05B-\A,AI'GG
M4W!6%%PIPAG6;0&P:B 5$*TC_Y#70^9?QQ^)*!Q_ABOI/=3QOY?515)=E(0=
MX[!8LJ&1<;4#+=$[7-4=1&;&[>J<M*R)/I88@6?5!>4Z:5T*$C90/4D0*[ <
M\>UR9)1ZRYX@=1T*R\T-EI9FW2ZRF=V2!#E(&7Z9@ =Y?U#09B5^"G%C+\XJ
M6DGS;T!J236036ZVH)J:@X6W@[PI(B8U2UDW9\7,0I9VQ^P6WV*U*)RZ9)0W
MP[HX80#!238W)P;/8HWSHR;+PL%4MHB :/9),WE&W@IKD@RSYLP[H&;1]@<)
M$L##:)A9&@Z,.U/T)P+TB6%Q$\0E:PO&A^D.X G.X&!@= 5>2G/VS<8/)W C
MB"":J1S@L79 ? .!!5[NH;M*!4%-"K>\TI(+O:0I'@+ 2^9OX^PW-_1AT((C
M/OXNN+@'M2$ Z 1+[N#&!0<<+<.NN)QF"W-O1$ATWWJY9$ZB@CFF';:R@8^(
MJ"?-K][<4.^V4H 8<X'KM@:>=.\A3D CYD_N>*0[XO<)-.X*0 BV[>(=+*MD
M3+B?!"S-X*6;&[O[L%N"9;K[ "; 3U:C?,FB+CDBY-K=Q_L'*;0K"YU!(/3U
MYWV1;\4$VRY965;S<LA,"18F"4!:"R'LE%^>5Q,@E:^+"6#$CJ(;H+"2X$ W
M\9OJ+3N*![7V?%AX\<WM/1DH&=;S///_R0^OGIY49696>F1,S5=/D]-B;(0:
MP.Z"QF9F#7.VAPN^4.:SV12GDU-52@TH(PWB79&L5RCK$241?G\+I K#P#B0
MK0F,=S[3<(R\5=ZW!?$;F$ ((I@.KUD$(VV! #PY,<ZH4;]3X!_/Z*)GHVK6
M,LI92_"-=3ZM6I XQI2F'O9A-6^*$M3'\/*UQ'6!J'5!(%[&1232V6R"H%^
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MWJH8*87%G_WVXI^@.K_[^?C-:_./_P-02P,$%     @ XVH+4P:8 C&=#0
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M<+6_=W0SE@.9009M[+G_,.%]Y9Y+:>;1]^GE(T1]ME5GG5:G_=3GTA,>18T
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M5](%C1&G"(9(-)L/TNF.!_]NQ2-;(E\-7$**3&PCVG7$5@HE"9=N8Q6K!B1
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M=7CXJ[^3G?"'@O\!4$L! A0#%     @ XVH+4U&*W)4R P   0P  !$
M         ( !     &)I=FDM,C R,3 X,#@N>'-D4$L! A0#%     @ XVH+
M4^(4P@+\"@  ?X8  !4              ( !80,  &)I=FDM,C R,3 X,#A?
M;&%B+GAM;%!+ 0(4 Q0    ( .-J"U/]<DS160<  .)7   5
M  "  9 .  !B:79I+3(P,C$P.# X7W!R92YX;6Q02P$"% ,4    " #C:@M3
MDPY'B_07  #4J   %               @ $<%@  8FEV:2TR,#(Q,#@Q,5\X
M:RYH=&U02P$"% ,4    " #C:@M3QHI=;-^M  #-G0, &0
M@ %"+@  8FEV:2TR,#(Q,#@Q,5\X:V5X,7HQ+FAT;5!+ 0(4 Q0    ( .-J
M"U,&F (QG0T  %M!   9              "  5C<  !B:79I+3(P,C$P.#$Q
M7SAK97@U>C$N:'1M4$L! A0#%     @ XVH+4_);K>1H#0  .R8  !H
M         ( !+.H  &)I=FDM,C R,3 X,3%?.&ME>#DY>C$N:'1M4$L! A0#
M%     @ XVH+4^CQ93K%#0  ,2@  !H              ( !S/<  &)I=FDM
K,C R,3 X,3%?.&ME>#DY>C(N:'1M4$L%!@     (  @ )0(  ,D% 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
